非甾体抗炎药|对乙酰氨基酚|Acetaminophen	3	1183547855	rs8330	UGT1A	Other	acetaminophen	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							CG	Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							GG	Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
	3	1183549413	rs8330	UGT1A;UGT1A9	Toxicity	acetaminophen	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							CG	Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							GG	Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
	3	1183614816	rs10929303	UGT1A	Other	acetaminophen	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							CT	Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							TT	Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
	3	1183614825	rs10929303	UGT1A	Toxicity	acetaminophen	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							CT	Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							TT	Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
	3	1183614855	rs1042640	UGT1A	Other	acetaminophen	CC	Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							CG	Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
							GG	Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.		
	3	1183614860	rs1042640	UGT1A	Toxicity	acetaminophen	CC	Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							CG	Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
							GG	Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.		
	3	1446908672	rs12746200	PLA2G4A	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
	3	1446908679	rs1805034	TNFRSF11A	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	CC	Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
							CT	Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
							TT	Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
	3	1446908686	rs2228246	PLCG1	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
							AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
							GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
	3	1449161156	rs9933632		Toxicity	acetaminophen;ibuprofen;loxoprofen;salicylamide	GG	Patients with the GG genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
							GT	Patients with the GT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
							TT	Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
	3	1449161162	rs6500265		Toxicity	acetaminophen;ibuprofen;loxoprofen;salicylamide	CC	Patients with the CC genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
							CT	Patients with the CT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
							TT	Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.		
	3	1449645356	rs767263838	SULT1A3	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645386	rs757573592	SULT1A3;SULT1A4	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645414	rs776817009	SULT1A3	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							AC	Patients with the AC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CC	Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645432	rs762151655	SULT1A3	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645456	rs750575779	SULT1A3	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							AG	Patients with the AG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							GG	Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645474	rs553050853	SULT1A3	Metabolism/PK	acetaminophen	GG	Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							GT	Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645498	rs751527244	SULT1A3	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							AC	Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							AT	There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.		
							CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645531	rs1293732453	SULT1A3	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							CT	Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1449645555	rs1328799050	SULT1A3	Metabolism/PK	acetaminophen	GG	Patients with the GG genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							GT	Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
							TT	Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.		
	3	1450374089	rs1042028	SULT1A1	Efficacy	acetaminophen	CC	Patients with the CC genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							CT	Patients with the CT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							TT	Patients with the TT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
	3	1450374095	rs224534	TRPV1	Efficacy	acetaminophen	AA	Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							AG	Patients with the AG genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							GG	Patients with the GG genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
	3	1450374101	rs1902023	UGT2B15	Efficacy	acetaminophen	AA	Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							AC	Patients with the AC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
							CC	Patients with the CC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.		
	3	1450826981	rs1799971	OPRM1	Efficacy	acetaminophen;tramadol	AA	Patients with the rs1799971 AA genotype may have an increased response to combined acetaminophen and tramadol as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.		
							AG	Patients with the rs1799971 AG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.		
							GG	Patients with the rs1799971 GG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.		
	3	1450936169	rs765399160	SULT1A1	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have decreased levels of acetaminophen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							CT	Patients with the CT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							TT	Patients with the TT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936189	rs28374453	NPIPB8;SULT1A1	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							AG	Patients with the AG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							GG	Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936211	rs1042028	SULT1A1	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminphen sulfation.		
							CT	Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.		
							TT	Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.		
	3	1450936217	rs72547527	SULT1A1	Metabolism/PK	acetaminophen	CC	Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							CT	Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							TT	Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936236	rs1042008	SULT1A1	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							AG	Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							GG	Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936254	rs767487725	SULT1A1	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							AC	Patients with the AC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							CC	Patients with the CC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936284	rs758145522	SULT1A1	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							AT	Patients with the AT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							TT	Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936290	rs544820732	SULT1A1	Metabolism/PK	acetaminophen	AA	Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							AG	Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							GG	Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
	3	1450936314	rs552524124	SULT1A1	Metabolism/PK	acetaminophen	GG	Patients with the GG genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							GT	Patients with the GT genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.		
							TT	Patients with the TT genotype may have increased sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.		
生物制剂|阿达木单抗|Adalimumab	3	1183615424	rs767455	TNFRSF1A	Efficacy	adalimumab;etanercept;infliximab	CC	Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
							CT	Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
							TT	Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
	3	1183700527	rs10919563	PTPRC	Efficacy	adalimumab;etanercept;infliximab;Tumor necrosis factor alpha (TNF-alpha) inhibitors	AA	Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
							AG	Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
							GG	Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
	3	1184169936	rs1801274	FCGR2A	Efficacy	adalimumab;infliximab	AA	Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							GA	Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							GG	Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
	3	1444673156	rs396991	FCGR3A	Efficacy	adalimumab;etanercept;infliximab	AA	Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
							AC	Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
							CC	Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
	3	1444702664	rs3761847	TRAF1	Efficacy	adalimumab;etanercept;infliximab;Tumor necrosis factor alpha (TNF-alpha) inhibitors	AA	Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
							AG	Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
							GG	Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
	3	1444703171	rs1800795	IL6	Efficacy	adalimumab;etanercept;infliximab	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
							CG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
							GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
	3	1445401325	rs10210302	ATG16L1	Efficacy	adalimumab	CC	Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.		
							CT	Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.		
							TT	Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.		
	3	1447952819	rs1059150	ATP5F1E	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	GG	Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							GT	Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							TT	Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
	3	1447952831	rs1264457	HLA-E	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	AA	Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							AG	Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							GG	Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
	3	1448100222	rs2071303	HFE	Efficacy	adalimumab	CC	Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.		
							CT	Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.		
							TT	Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.		
	3	1448100235	rs1799852	TF	Efficacy	adalimumab	CC	Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.		
							CT	Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.		
							TT	Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.		
	3	1448100404	rs1130864	CRP	Efficacy	adalimumab	AA	Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.		
							AG	Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.		
							GG	Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.		
	3	1448100426	rs9373839	ATG5	Efficacy	adalimumab	CC	Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.		
							CT	Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.		
							TT	Patients with the TT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.		
	3	1448100437	rs510432	ATG5	Efficacy	adalimumab	CC	Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.		
							CT	Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.		
							TT	Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.		
	3	1448266599	rs2302489	KLRD1	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	AA	Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.		
							AT	Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.		
							TT	Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.		
	3	1448266609	rs7301582	KLRC1	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	CC	Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
							CT	Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
							TT	Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
	3	1451106265	rs9828223		Efficacy	adalimumab	CC	Patients with Crohn disease and the CC genotype may have be less likely to develop anti-adalimumab antibodes and therefore may have an increased response to adalimumab therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to adalimumab.		
							CT	Patients with Crohn disease and the CT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.		
							TT	Patients with Crohn disease and the TT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.		
降尿酸药|别嘌呤醇|Allopurinol	3	1184764189	rs2844665		Toxicity	allopurinol	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
	3	1184764194	rs3094188	PSORS1C3	Toxicity	allopurinol	AA	Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							AC	Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							CC	Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
	3	1184764199	rs3130501	POU5F1	Toxicity	allopurinol	AA	Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							AG	Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							GG	Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
	3	1184764204	rs3130931	POU5F1	Toxicity	allopurinol	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
	3	1184764228	rs9469003	CYCSP5	Toxicity	allopurinol	CC	Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							CT	Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
							TT	Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.		
	3	1447982582	rs2231142	ABCG2	Efficacy	allopurinol	GG	Patients with the GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.		
							GT	Patients with the GT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.		
							TT	Patients with the TT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.		
	3	1448428918	rs34650714	UGT1A1;UGT1A10;UGT1A3;UGT1A4;UGT1A5;UGT1A6;UGT1A7;UGT1A8;UGT1A9	Dosage	allopurinol;febuxostat	CC	Patients with the CC genotype and gout may require a dose of 300 mg/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
							CT	Patients with the CT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
							TT	Patients with the TT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
	3	1448428937	rs75995567	AOX1	Dosage	allopurinol;febuxostat	CC	Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							CT	Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							TT	Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
	3	1448428944	rs3731722	AOX1	Dosage	allopurinol;febuxostat	AA	Patients with the AA genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							AG	Patients with the AG genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							GG	Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
	3	1449157530	rs3131003	PSORS1C1	Toxicity	allopurinol	AA	Patients with the AA genotype who are administered allopurinol may have an decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
							AG	Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
							GG	Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
	3	1449157547	rs3099844	CYCSP5	Toxicity	allopurinol	AA	Patients with the AA genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.		
							AC	Patients with the AC genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.		
							CC	Patients with the CC genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA or AC genotypes. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.		
	3	1449157600	rs367398	NOTCH4	Toxicity	allopurinol	AA	Patients with the AA genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
							AG	Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
							GG	Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.		
	3	1449170133	rs9263726	PSORS1C1	Toxicity	allopurinol	AA	Patients with the AA genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
							AG	Patients with the AG genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
							GG	Patients with the GG genotype and who are treated with allopurinol may have a decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA or AG genotypes. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
	3	1449170150	rs2734583		Toxicity	allopurinol	AA	Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
							AG	Patients with the AG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
							GG	Patients with the GG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.		
	3	1450375674	rs61816456	NTNG1	Efficacy	allopurinol	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375680	rs77567654	GREM2	Efficacy	allopurinol	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375686	rs10802887	GREM2	Efficacy	allopurinol	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375692	rs1934341	GREM2	Efficacy	allopurinol	CC	Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CG	Patients with the CG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GT	Patients with the GT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375701	rs4659982	GREM2	Efficacy	allopurinol	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AC	Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AT	Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375710	rs79663562	MYT1L	Efficacy	allopurinol	CC	Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375716	rs10193126	TRIB2	Efficacy	allopurinol	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375722	rs57449396	TBL1XR1	Efficacy	allopurinol	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375728	rs2725215	PKD2	Efficacy	allopurinol	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375734	rs4148157	ABCG2	Efficacy	allopurinol	AA	Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AG	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
	3	1450375740	rs76979899	ABCG2	Efficacy	allopurinol	CC	Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
							CT	Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
							TT	Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
	3	1450375746	rs4148155	ABCG2	Efficacy	allopurinol	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
							AG	Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
							GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s		
	3	1450375758	rs9366772	HLA-C	Efficacy	allopurinol	AA	Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							AG	Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
							GG	Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.		
高血压药|氨氯地平|amlodipine	3	1183594148	rs4291	ACE	Efficacy	amlodipine;chlorthalidone;lisinopril	AA	Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
							AT	Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
							TT	Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
	3	1183615177	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	CYP3A5	Metabolism/PK	amlodipine	*1/*1	Patients with the *1/*1 genotype may have increased metabolism of amlodipine as compared to patients carrying at least one copy of the *3, *6 or *7 alleles. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.		
							*3	Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.	No function	
							*6	Patients carrying at least one copy of the *6 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.	No function	
							*7	Patients carrying at least one copy of the *7 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.	No function	
	3	1446908603	rs11122576	AGT	Efficacy	amlodipine;chlorthalidone;lisinopril	CC	Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.		
							CT	Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.		
							TT	No information were reported regarding patients with the TT genotype.		
	3	1446908615	rs11122576	AGT	Efficacy	amlodipine;chlorthalidone;lisinopril	CC	Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.		
							CT	Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.		
							TT	No information were reported regarding patients with the TT genotype.		
	3	1447983137	rs12143842		Efficacy	amlodipine;chlorthalidone;lisinopril	CC	Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.		
							CT	Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.		
							TT	No information were reported regarding patients with the TT genotype.		
	3	1447983151	rs200148		Toxicity	amlodipine;chlorthalidone;lisinopril	AA	Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.		
							AG	Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.		
							GG	No information were reported regarding patients with the GG genotype.		
	3	655384767	rs5065	NPPA	Efficacy	amlodipine;chlorthalidone	AA	Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.		
							AG	Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.		
							GG	Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.		
抗感染药|阿莫西林|amoxicillin	3	827849095	rs9274407	HLA-DQB1	Toxicity	amoxicillin;clavulanate	AA	Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.		
							AT	Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.		
							TT	Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.		
抗凝药|阿司匹林|aspirin	3	1043858637	rs7572857	CEP68	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							AG	Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							GG	Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
	3	1043858642	rs7179742	FSIP1	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							AG	Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
	3	1043858651	rs3856806	PPARG	Toxicity	aspirin	CC	Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.		
							CT	Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.		
							TT	Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.		
	3	1043858656	rs2243250	IL4	Toxicity	aspirin	CC	Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858661	rs2228079	ADORA1	Toxicity	aspirin	GG	Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							GT	Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
	3	1043858666	rs16851030	ADORA1	Toxicity	aspirin	CC	Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							CT	Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
	3	1043858675	rs1613662	GP6	Efficacy	aspirin	AA	Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AG	Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858680	rs11587213	FCER1G	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
							AG	Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
							GG	Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
	3	1043858685	rs1143627	IL1B	Toxicity	aspirin	AA	Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.		
							AG	Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.		
							GG	Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.		
	3	1043858698	rs1131882	TBXA2R	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							AG	Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
							GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.		
	3	1043858703	rs1062535	ITGA2	Efficacy	aspirin	AA	Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AG	Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858722	rs2768759	NTRK1	Efficacy	aspirin	AA	Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AC	No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CC	Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858733	rs1050891	HNMT	Toxicity	aspirin	AA	Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
							AG	Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
							GG	Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.		
	3	1043858970	rs5985	F13A1	Efficacy	aspirin	AA	Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AC	Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CC	Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858975	rs4523	TBXA2R	Efficacy	aspirin	AA	Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.		
							AG	Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.		
							GG	Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.		
	3	1043858980	rs6065	GP1BA	Efficacy	aspirin	CC	Patients with the rs6065 CC genotype may have a decreased response and an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the rs6065 CT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the rs6065 TT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1043858990	rs10306114	PTGS1	Efficacy	aspirin	AA	Patients with the rs10306114 AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to aspirin.		
							AG	Patients with the rs10306114 AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.		
							GG	Patients with the rs10306114 GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.		
	3	1043859274	rs1062535	ITGA2	Efficacy	aspirin;clopidogrel	AA	Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.		
							AG	Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.		
							GG	Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.		
	3	1043859297	rs10306114	PTGS1	Efficacy	aspirin;clopidogrel	AA	Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							AG	Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							GG	Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
	3	1183681861	rs12041331	PEAR1	Efficacy;Toxicity	aspirin;clopidogrel	AA	Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.		
							AG	Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.		
							GG	Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.		
	3	1183681866	rs12041331	PEAR1	Toxicity	aspirin	AA	Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.		
							AG	Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.		
							GG	Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.		
	3	1184516153	G6PD B (wildtype), G6PD liumm_special_G6PD1	G6PD	Toxicity	aspirin	B (wildtype)	Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.	Class IV	
							B (wildtype)/B (wildtype)	Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
							Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Male children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
							Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/B (wildtype)	Female patients heterozygous for the G6PD Mediterranean variant with systemic arthritis who are treated with a high dose of aspirin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with homozygous for the G6PD Mediterranean variant or B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
							Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham/Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Female children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B/B (wildtype) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
	3	1444667175	rs28360521	CYP2D6	Toxicity	aspirin	CC	Patients with the CC genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.		
							CT	Patients with the CT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.		
							TT	Patients with the TT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.		
	3	1444667432	rs3818822	CHIA	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							GG	Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667461	rs1047626	SLC30A9	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							GG	Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667499	rs3097671	HLA-DPB1	Toxicity	aspirin	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CG	Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							GG	Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667512	rs1042136	HLA-DPB1	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667537	rs1042151	HLA-DPB1	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							GG	Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667549	rs3129294	HLA-DPB2	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667566	rs3130100	ZBTB22	Toxicity	aspirin	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CT	Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							TT	Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667578	rs1074373		Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AC	Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CC	Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667585	rs7862221	TSC1	Toxicity	aspirin	CC	Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							CT	Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							TT	Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444667592	rs11819745	THRA	Toxicity	aspirin	AA	Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							AG	Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
							GG	Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.		
	3	1444700452	rs1059288	TAPBP	Toxicity	aspirin	AA	Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AG	Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444700466	rs2071888	TAPBP	Toxicity	aspirin	CC	Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CG	Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444700639	rs1126510	PTGIR	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.		
							AG	Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.		
							GG	Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.		
	3	1444700830	rs1353411	PTGER2	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AG	Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703146	rs1800469	TGFB1	Toxicity	aspirin	AA	Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							AG	Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							GG	Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
	3	1444703339	rs2075797	PTGER2	Toxicity	aspirin	CC	Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CG	Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GG	Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703346	rs2108622	CYP4F2	Other	aspirin;clopidogrel	CC	Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							CT	Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							TT	Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
	3	1444703487	rs7551789	PTGER3	Toxicity	aspirin	AA	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AT	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703495	rs4292	ACE	Toxicity	aspirin	CC	Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703502	rs4291	ACE	Toxicity	aspirin	AA	Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							AT	Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703509	rs3775291	TLR3	Toxicity	aspirin	CC	Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444703521	rs5050	AGT	Toxicity	aspirin	GG	Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							GT	Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1444704795	rs10279545	COL26A1	Toxicity	aspirin	CC	Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.		
	3	1446908672	rs12746200	PLA2G4A	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
							GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.		
	3	1446908679	rs1805034	TNFRSF11A	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	CC	Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
							CT	Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
							TT	Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.		
	3	1446908686	rs2228246	PLCG1	Toxicity	acetaminophen;aspirin;diclofenac;propionic acid derivatives;Pyrazolones	AA	Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
							AG	Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
							GG	Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.		
	3	1447964324	rs4271002	NAT2	Toxicity	aspirin	CC	Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.		
							CG	Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.		
							GG	Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.		
	3	1447979279	rs6962291	TBXAS1	Toxicity	aspirin	AA	Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
							AT	Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
							TT	Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
	3	1447990846	rs2965667		Other	Antiinflammatory agents, non-steroids;aspirin	AA	Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.		
							AT	Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.		
							TT	Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.		
	3	1448097822	rs16973225		Other	Antiinflammatory agents, non-steroids;aspirin	AA	Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.		
							AC	Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.		
							CC	Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.		
	3	1448101059	rs557881	SLC6A12	Toxicity	aspirin	AA	Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
							AG	Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
							GG	Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.		
	3	1448101102	rs12042763	PTGS2	Efficacy	aspirin	GG	Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.		
							GT	Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.		
							TT	Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.		
	3	1448617231	rs1131882	TBXA2R	Efficacy;Toxicity	aspirin	AA	Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.		
							AG	Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.		
							GG	Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin.		
	3	1449169668	rs2070959	UGT1A6	Efficacy	aspirin	AA	Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AG or GG genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
							AG	Patients with the AG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
							GG	Patients with the GG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
	3	1449169675	rs1105879	UGT1A6	Efficacy	aspirin	AA	Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AC or CC genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
							AC	Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
							CC	Patients with the CC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.		
	3	1450928601	rs12041331	PEAR1	Efficacy	aspirin;clopidogrel;prasugrel	AA	Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
							AG	Patients with the AG genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the GG genotype but higher platelet aggregation as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
							GG	Patients with the GG genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
	3	1450928608	rs2768759	NTRK1;PEAR1	Efficacy	aspirin;prasugrel	AA	Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AC or CC genotypes. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
							AC	Patients with the AC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
							CC	Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.		
	3	613979643	rs730012	LTC4S	Toxicity	aspirin	AA	Patients with the rs730012 AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for urticaria.		
							AC	Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.		
							CC	Patients with the rs730012 CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.		
	3	981204107	rs20417	PTGS2	Efficacy	aspirin	CC	Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.		
							CG	Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.		
							GG	Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.		
	3	982031045	rs1799983	NOS3	Toxicity	aspirin;Beta Blocking Agents;clopidogrel;hmg coa reductase inhibitors	GG	Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.		
							TG	Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.		
							TT	Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.		
	3	982037378	rs1126643	ITGA2	Efficacy	aspirin;clopidogrel	CC	Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							CT	Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
							TT	Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.		
	3	982040717	rs1065776	P2RY1	Efficacy	aspirin	CC	Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							CT	Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.		
							TT	Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.		
高血压药|阿替洛尔|Atenolol	3	1043859020	rs5051	AGT	Efficacy	atenolol	CC	Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.		
							CT	Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.		
							TT	Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.		
	3	1043880783	rs11039149	NR1H3	Toxicity	atenolol;verapamil	AA	Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.		
							GA	Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.		
							GG	Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.		
	3	1043880792	rs5443	GNB3	Efficacy	atenolol	CC	Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.		
							CT	Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.		
							TT	Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.		
	3	1183533972	rs2301339	GNB3	Efficacy	atenolol	AA	Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.		
							AG	Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol.		
							GG	Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.		
	3	1183564259	rs5370	EDN1	Efficacy	atenolol;irbesartan	GG	Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
							GT	Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
							TT	No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
	3	1183614509	rs1800545	ADRA2A	Efficacy	atenolol	AA	Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.		
							AG	Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.		
							GG	Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.		
	3	1183614807	rs11064426	GNB3	Efficacy	atenolol	AA	Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.		
							AC	Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.		
							CC	Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.		
	3	1183615582	rs699	AGT	Efficacy	atenolol	AA	Patients with the rs699 AA genotype may have a decreased response to atenolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.		
							AG	Patients with the rs699 AG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.		
							GG	Patients with the rs699 GG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.		
	3	1184986985	rs4648287	PTGS2	Toxicity	atenolol	AA	Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							AG	Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							GG	Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1184986992	rs10157410	PLA2G4A	Toxicity	atenolol	CC	Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							CG	Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							GG	Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1184987008	rs2144297	GALNT2	Toxicity	atenolol	CC	Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
							CT	Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
							TT	Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
	3	1184987030	rs2144300	GALNT2	Other	atenolol	CC	Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
							CT	Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
							TT	Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.		
	3	1184987041	rs3213619	ABCB1	Toxicity	atenolol	AA	Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							AG	Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							GG	Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1184987048	rs10267099	ABCB1	Toxicity	atenolol	AA	Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							AG	Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							GG	Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1184987055	rs12595985	FTO	Toxicity	atenolol	AA	Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							AC	Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							CC	Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1184987062	rs9940629	FTO	Toxicity	atenolol	AA	Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							AG	Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
							GG	Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		
	3	1444704784	rs1024323	GRK4	Toxicity	atenolol;verapamil	CC	Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.		
							CT	Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.		
							TT	Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.		
	3	1446902898	rs12346562		Efficacy	atenolol;bisoprolol	AA	Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.		
							AC	Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.		
							CC	Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.		
	3	1446902912	rs1104514		Efficacy	atenolol	AA	Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.		
							AG	Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.		
							GG	Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.		
	3	1446902920	rs10739150		Efficacy	atenolol	GG	Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.		
							GT	Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.		
							TT	Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.		
	3	1447814391	rs201279313	SLC25A31	Efficacy	atenolol;hydrochlorothiazide;metoprolol	TTA/TTA	Patients with the TTA/TTA genotype and hypertension may have decreased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/del genotype. Other genetic and clinical factors may also influence a patient's response.		
							TTA/del	Patients with the TTA/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response.		
							del/del	No patients with del/del were studied. However, patients with the del/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA/TTA genotype. Other genetic and clinical factors may also influence a patient's response.		
	3	1447943614	rs11313667	LRRC15	Efficacy	atenolol	C/del	Patients with the C/del genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.		
							CC	Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.		
							del/del	Patients with the del/del genotype and hypertension may have increased response to atenolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to atenolol.		
	3	1447943772	rs1367094	ZMAT4	Efficacy	atenolol	CC	Patients with genotype CC and hypertension have decreased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol.		
							CT	Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol.		
							TT	Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.		
	3	1447960204	rs1042714	ADRB2	Toxicity	atenolol;metoprolol	CC	Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.		
							CG	Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.		
							GG	Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.		
	3	1447962613	rs340874	PROX1	Toxicity	atenolol	CC	Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
							CT	Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
							TT	Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.		
	3	1447986967	rs11649514	PRKCB	Toxicity	atenolol	GG	Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.		
							GT	Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.		
							TT	Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.		
	3	1448602385	rs11124945	PLEKHH2	Toxicity	atenolol;verapamil	AA	Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.		
							AG	Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.		
							GG	Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.		
	3	1448602689	rs2669429	DPYS	Toxicity	atenolol	AA	Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.		
							AG	Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.		
							GG	Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.		
	3	1449576301	rs35123024		Efficacy	atenolol;hydrochlorothiazide	CC	Patients with the CC genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
							CT	Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
							TT	Patients with the TT genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
	3	1449576307	rs261316	ALDH1A2	Efficacy	atenolol;hydrochlorothiazide	CC	Patients with the CC genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
							CT	Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
							TT	Patients with the TT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.		
	3	1450930536	rs7606603	XIRP2	Efficacy	atenolol	CC	Patients with hypertension and the CC genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							CT	Patients with hypertension and the CT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							TT	Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	1450930542	rs16872401		Efficacy	atenolol	CC	Patients with hypertension and the CC genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							CT	Patients with hypertension and the CT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							TT	Patients with hypertension and the TT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	1450930554	rs7184292		Efficacy	atenolol	AA	Patients with hypertension and the AA genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							AG	Patients with hypertension and the AG genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							GG	Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	1450930560	rs7184292		Dosage	atenolol	AA	Patients with hypertension and the AA genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.		
							AG	Patients with hypertension and the AG genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.		
							GG	Patients with hypertension and the GG genotype may require a decreased dose of atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect atenolol dose.		
	3	1451106200	rs45545233	SLC4A1	Efficacy	atenolol;metoprolol	CC	Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.		
							CT	Patients with hypertension and the CT genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.		
							TT	Patients with hypertension and the TT genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.		
	3	1451106206	rs294610		Efficacy	atenolol;metoprolol	AA	Patients with hypertension and the AA genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.		
							AC	Patients with hypertension and the AC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.		
							CC	Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.		
	3	1451107342	rs1042713	ADRB2	Efficacy	atenolol;metoprolol	AA	Patients with the AA genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the AG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
							AG	Patients with the AG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
							GG	Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
	3	1451107360	rs1042714	ADRB2	Efficacy	atenolol;metoprolol	CC	Patients with the CC genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
							CG	Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
							GG	Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.		
	3	1451117590	rs9306160	RRP1B	Efficacy	atenolol	CC	Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							CT	Patients with hypertension and the CT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							TT	Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	1451118326	rs4387287	STN1	Efficacy	atenolol	AA	Patients with hypertension and the AA genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							AC	Patients with hypertension and the AC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							CC	Patients with hypertension and the CC genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patient with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	1451118332	rs8068318	TBX2	Efficacy	atenolol	CC	Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							CT	Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.		
							TT	Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.		
	3	655385404	rs688	LDLR	Efficacy	atenolol	CC	Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.		
							CT	Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.		
							TT	Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.		
	3	827863928	rs1051375	CACNA1C	Efficacy	atenolol;verapamil	AA	Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment.		
							AG	Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.		
							GG	Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.		
降脂药|阿托伐他汀|Atorvastatin	1A	1043880818	rs4149056	SLCO1B1	Toxicity	atorvastatin	CC	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		
							CT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		
							TT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		
	2A	1451244800	rs4149056	SLCO1B1	Metabolism/PK	atorvastatin	CC	Patients with the CC genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		
							CT	Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		
							TT	Patients with the TT genotype may have decreased exposure to atorvastatin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		
	2B	1183492249	rs7412	APOE	Efficacy	atorvastatin	CC	Patients with the rs7412 CC genotype may have decreased response to atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.		
							CT	Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.		
							TT	Patients with the rs7412 TT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.		
免疫抑制剂|硫唑嘌呤|azathioprine	1A	1184514050	rs116855232	NUDT15	Toxicity	azathioprine	CC	Patients with the rs116855232 CC genotype and inflammatory bowel diseases who are treated with azathioprine may have a reduced, but not absent risk of myelosuppression as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.		
							CT	Patients with the rs116855232 CT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.		
							TT	Patients with the rs116855232 TT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.		
	1A	1451237240	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C	TPMT	Toxicity	azathioprine	*1	Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.	Normal function	
							*2	Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of myelosuppression when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.	No function	
							*3A	Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of myelosuppression when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.	No function	
							*3B	Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of myelosuppression when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.	No function	
							*3C	Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of myelosuppression when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.	No function	
	1A	1451237326	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C	TPMT	Dosage	azathioprine	*1	Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.	Normal function	
							*2	Patients with the *2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.	No function	
							*3A	Patients with the *3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.	No function	
							*3B	Patients with the *3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.	No function	
							*3C	Patients with the *3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine dosage.	No function	
高血压药|贝那普利|Benazepril	3	1183614466	rs1805087	MTR	Efficacy	benazepril	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.		
							AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.		
							GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.		
	3	1183614605	rs1799998	CYP11B2	Efficacy	benazepril;imidapril	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
							AG	Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
							GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
	3	1183615150	rs7079	AGT	Efficacy	benazepril	GG	Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.		
							GT	Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.		
							TT	Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.		
	3	1183615213	rs1801133	MTHFR	Efficacy	benazepril	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.		
							AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.		
							GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.		
	3	1183615621	rs2229437	PRCP	Efficacy	benazepril	GG	Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.		
							GT	Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.		
							TT	Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.		
	3	1444666376	rs5051	AGT	Efficacy	benazepril;imidapril	CC	Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
							CT	Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
							TT	Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
高血压药|比索洛尔|Bisoprolol	3	1446902898	rs12346562		Efficacy	atenolol;bisoprolol	AA	Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.		
							AC	Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.		
							CC	Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.		
	3	1448100514	rs2514036	ACY3	Efficacy	bisoprolol	CC	Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.		
							CT	Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.		
							TT	Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.		
高血压药|布新洛尔|Bucindolol	3	1451398281	rs1801253	ADRB1	Efficacy	bucindolol	CC	Patients with heart failure and the rs1801253 CC genotype may have an increased response to bucindolol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to bucindolol.		
							CG	Patients with heart failure and the rs1801253 CG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.		
							GG	Patients with heart failure and the rs1801253 GG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.		
	3	982046386	rs61767072	ADRA2C	Efficacy	bucindolol	GGGGCGGGGCCG/GGGGCGGGGCCG	Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.		
							GGGGCGGGGCCG/del	Patients with the GGGGCGGGGCCG/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.		
							del/del	Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.		
高血压药|卡维地洛|Carvedilol	3	1183615480	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10	CYP2D6	Metabolism/PK	carvedilol	*1	Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	Normal function	
							*10	Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	Decreased function (AV 0.25)	
							*2	Patients carrying the CYP2D6*2 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	Normal function	
							*3	Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	No function	
							*4	Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	No function	
							*6	Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.	No function	
	3	1183698813	rs4148323	UGT1A1	Other	carvedilol	AA	Patients with the AA (i.e. UGT1A1 *6/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.		
							AG	Patients with the AG (i.e. UGT1A1 *1/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.		
							GG	Patients with the GG (i.e. UGT1A1 *1/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.		
	3	1449717812	CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*10	CYP2D6	Dosage	carvedilol	*1	Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased carvedilol dose requirements as compared to patients carrying two no function alleles or a no function allele in combination with a normal or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.	Normal function	
							*10	Patients carrying the CYP2D6*10 allele in combination with a no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.	Decreased function (AV 0.25)	
							*3	Patients carrying the CYP2D6*3 allele in combination with a decreased function allele with an activity value of 0.25 may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.	No function	
							*4	Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles, while patients carrying the *4 allele in combination with another no function allele may also have increased carvedilol dose requirements as compared to patients carrying a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.	No function	
	3	1451397981	rs1801252	ADRB1	Efficacy	carvedilol	AA	Patients with the rs1801252 AA genotype may have a decreased response to carvedilol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to carvedilol.		
							AG	Patients with the rs1801252 AG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.		
							GG	Patients with the rs1801252 GG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.		
	3	1451398000	rs1801253	ADRB1	Dosage	carvedilol	CC	Patients with heart failure and the rs1801253 CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.		
							CG	There is currently no available evidence regarding the association between the rs1801253 CG genotype and carvedilol dosage requirements. However, patients with heart failure and the CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.		
							GG	Patients with heart failure and the rs1801253 GG genotype may require increased doses of carvedilol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.		
	3	613979021	rs1042714	ADRB2	Efficacy	carvedilol	CC	Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.		
							CG	Patients with the CG genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.		
							GG	Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.		
非甾体抗炎药|塞来昔布|Celecoxib	1A	1451236700	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*13	CYP2C9	Metabolism/PK	celecoxib	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.	Normal function	
							*13	The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*13 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of celecoxib.	No function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.	No function	
抗凝药|氯吡格雷|Clopidogrel	1A	1043858794	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*10, CYP2C19*17, CYP2C19*19, CYP2C19*25, CYP2C19*26	CYP2C19	Metabolism/PK	clopidogrel	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele may have increased metabolism of clopidogrel as compared to patients with no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Normal function	
							*10	The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Decreased function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele with another increased function allele may have increased metabolism of clopidogrel compared to two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Increased function	
							*19	The CYP2C19*19 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*19 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Decreased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	No function	
							*25	The CYP2C19*25 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*25 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Decreased function	
							*26	The CYP2C19*26 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	Decreased function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	No function	
							*8	The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.	No function	
	1A	1451282340	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	CYP2C19	Efficacy	clopidogrel	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation compared to patients with two increased function alleles or a combination of a normal function allele with an increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.	Normal function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.	No function	
	1A	1451282440	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*8, CYP2C19*17	CYP2C19	Efficacy;Toxicity	clopidogrel	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele and cardiovascular disease who are treated with clopidogrel may have a decreased, but not absent, risk for adverse cardiovascular events as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	Normal function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
							*4	The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
							*5	The CYP2C19*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*5 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
							*6	The CYP2C19*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*6 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
							*8	The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for adverse cardiovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.	No function	
	2B	1451254525	rs71647871	CES1	Efficacy	clopidogrel	CC	Patients with the rs71647871 CC genotype who are treated with clopidogrel may have increased platelet aggregation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to clopidogrel.		
							CT	Patients with the rs71647871 CT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.		
							TT	Patients with the rs71647871 TT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.		
	2B	982030805	rs71647871	CES1	Metabolism/PK	clopidogrel	CC	Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.		
							CT	Patients with the rs71647871 CT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.		
							TT	Patients with the rs71647871 TT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.		
抗生素|复方磺胺甲恶唑（磺胺甲恶唑/甲氧苄啶）|Compound Sulfamethoxazole Tablets(Sulfamethoxazole/Trimethoprim)	3	1451496100	G6PD B (wildtype), G6PD liumm_special_G6PD2	G6PD	Toxicity	sulfamethoxazole	B (wildtype)	Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.	Class IV	
							Canton, Taiwan-Hakka, Gifu-like, Agrigento-like	Patients with one X-chromosome and the G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele (rs72554665 allele A, assigned as G6PD deficient) who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with the B (wildtype) allele (non-deficient, class IV). Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with another deficient class II allele who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with two copies of the B allele. Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with a non-deficient allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.	Class II	
	3	982047840	rs761142	GCLC	Toxicity	sulfamethoxazole	AA	Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.		
							AC	Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.		
							CC	Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.		
免疫抑制剂|环磷酰胺|cyclophosphamide	3	1043880293	rs3211371	CYP2B6	Toxicity	cyclophosphamide;doxorubicin	CC	Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.		
							TC	Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.		
							TT	Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.		
	3	1043880298	rs12721655	CYP2B6	Efficacy	cyclophosphamide;doxorubicin	AA	Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.		
							AG	Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.		
							GG	Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution "the relevance of these data is uncertain, given the low number of rare alleles". Other clinical or genetic factors may also influence a patient's response.		
	3	1147261601	rs6413432	CYP2E1	Efficacy	cisplatin;cyclophosphamide	AA	The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.		
							AT	Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.		
							TT	Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.		
	3	1148480056	rs2070676	CYP2E1	Efficacy;Toxicity	cisplatin;cyclophosphamide	CC	Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.		
							CG	Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.		
							GG	Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.		
	3	1153928101	rs1143684	NQO2	Efficacy	cyclophosphamide;doxorubicin	CC	Patients with the CC genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.		
							CT	Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.		
							TT	Patients with the TT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.		
	3	1183680575	rs12210538	SLC22A16	Toxicity	cyclophosphamide;doxorubicin	AA	Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		
							AG	Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		
							GG	Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		
	3	1183703000	rs2010963	VEGFA	Efficacy	cyclophosphamide	CC	Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.		
							CG	Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.		
							GG	Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.		
	3	1183704287	rs723685	SLC22A16	Dosage	cyclophosphamide;doxorubicin	AA	Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		
							AG	Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		
							GG	Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		
	3	1183704358	rs6907567	SLC22A16	Efficacy;Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
							AG	Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
							GG	Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
	3	1183704414	rs6151031	ALDH1A1	Toxicity	carboplatin;cyclophosphamide;thiotepa	CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC	Patients with the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype may have decreased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/del or del/del. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.		
							CTGGTGAGGAGAGAACC/del	Patients with the CTGGTGAGGAGAGAACC/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.		
							del/del	Patients with the del/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.		
	3	1184348703	rs3219484	MUTYH	Toxicity	cisplatin;cyclophosphamide	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							TT	Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
	3	1184348708	rs1051740	EPHX1	Toxicity	cisplatin;cyclophosphamide	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
	3	1184348713	rs698	ADH1C	Efficacy	cisplatin;cyclophosphamide	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
							TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
	3	1184348718	rs1142345	TPMT	Efficacy	cisplatin;cyclophosphamide	CC	Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
							TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.		
	3	1184348731	rs1801280	NAT2	Toxicity	cisplatin;cyclophosphamide	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
	3	1184348774	rs1052536	LIG3	Toxicity	cisplatin;cyclophosphamide	CC	Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							CT	Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
							TT	Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.		
	3	1184512128	rs3824662	GATA3	Efficacy	asparaginase;cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;leucovorin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							AC	Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							CC	Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
	3	1444607986	CYP2B6*1, CYP2B6*6	CYP2B6	Efficacy;Toxicity	cyclophosphamide	*1/*1	Patients with the *1/*1 genotype and chronic lymphocytic leukemia may be more likely to achieve a complete response but also more likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*6 or *6/*6 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.		
							*1/*6	Patients with the *1/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.		
							*6/*6	Patients with the *6/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.		
	3	1445401001	rs1056836	CYP1B1	Efficacy	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
							CG	Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
							GG	Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
	3	1445401179	rs1570360	VEGFA	Efficacy	cyclophosphamide;docetaxel	AA	Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.		
							AG	Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.		
							GG	Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.		
	3	1445737062	rs1799983	NOS3	Efficacy	anthracyclines and related substances;cyclophosphamide;doxorubicin;epirubicin;fluorouracil;methotrexate;oxaliplatin;Platinum compounds	GG	Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.		
							GT	Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.		
							TT	Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.		
	3	1446907957	rs7254579	CYP2B6	Metabolism/PK	cyclophosphamide	CC	Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.		
							CT	Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.		
							TT	Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.		
	3	1446908002	rs4802101	CYP2B6	Toxicity;Metabolism/PK	cyclophosphamide	CC	Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.		
							CT	Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.		
							TT	Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.		
	3	1447945787	CYP2B6*1, CYP2B6*6	CYP2B6	Metabolism/PK	cyclophosphamide	*1/*1	Children with the CYP2B6*1/*1 diplotype and B-cell non-Hodgkin's lymphoma may have increased clearance of cyclophosphamide as compared to children with the *1/*6 or *6/*6 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.		
							*1/*6	Children with the CYP2B6*1/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.		
							*6/*6	Children with the CYP2B6*6/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.		
	3	1447945800	rs1056836	CYP1B1	Toxicity	cyclophosphamide;epirubicin;paclitaxel	CC	Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
							CG	Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
							GG	Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)		
	3	1447945850	rs2229109	ABCB1	Toxicity	bleomycin;cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine;vindesine	CC	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
							CT	Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
							TT	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
	3	1447953291	rs3957356	GSTA1	Efficacy	cyclophosphamide	CC	Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.		
							CT	Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.		
							TT	Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.		
	3	1447953328	rs4135385	CTNNB1	Efficacy;Toxicity	cyclophosphamide;dexamethasone;lenalidomide;thalidomide	AA	Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							AG	Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							GG	Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
	3	1447963611	rs351855	FGFR4	Efficacy	cyclophosphamide;fluorouracil;methotrexate	AA	Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.		
							AG	Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.		
							GG	Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time.		
	3	1447990283	rs639174	DROSHA	Toxicity	cyclophosphamide;cytarabine;daunorubicin;mercaptopurine;methotrexate;prednisone;vincristine	CC	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
							CT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
							TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
	3	1448098793	rs17021408		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099059	rs1891059		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099093	rs117532069	DOK5	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099112	rs79085477	BMP7	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099135	rs141059755	LINC00251	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099430	rs80223967		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							AG	Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							GG	Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
	3	1448099828	rs1801157	CXCL12	Efficacy	alemtuzumab;chlorambucil;cyclophosphamide;fludarabine;prednisone;rituximab;vincristine	CC	Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.		
							CT	Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.		
							TT	Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.		
	3	1448102294	rs3957357	GSTA1	Efficacy	cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine	AA	Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.		
							AG	Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.		
							GG	Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.		
	3	1448112147	rs4149056	SLCO1B1	Toxicity	cyclophosphamide;docetaxel;doxorubicin;epirubicin;fluorouracil	CC	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		
							CT	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		
							TT	Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		
	3	1448525559	rs1021737	CTH	Toxicity	busulfan;cyclophosphamide	GG	Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.		
							GT	Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.		
							TT	Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS.		
	3	1448624459	rs12050587	PIGB	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with the AA genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
							AG	Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
							GG	Patients with the GG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have Increased likelihood of neutropenia or leukopenia as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
	3	1448624484	rs11636687		Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with the CC genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased of likelihood of leukopenia or neutropenia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
							CT	Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
							TT	Patients with the TT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).		
	3	1448632697	rs738409	PNPLA3	Toxicity	asparaginase;cyclophosphamide;daunorubicin;prednisolone;vincristine	CC	Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
							CG	Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
							GG	Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
	3	1449270865	rs115457081	IRS1	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270871	rs112242273	GNL3	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270877	rs299293	HMMR	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270883	rs299313	HMMR	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270889	rs299314	HMMR	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270895	rs3805945	PPP2R5D	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270901	rs78428806	PERP	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but an increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270907	rs117101815	PERP	Toxicity	cyclophosphamide;epirubicin;fluorouracil	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270925	rs9402944	PERP	Toxicity	cyclophosphamide;epirubicin;fluorouracil	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270931	rs9389568	PERP	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270937	rs117458836	CYP2C8	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270943	rs118088833	TP53AIP1	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270949	rs149212925	NOS1	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270955	rs144991623	FOXO1	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270961	rs77769901	CCNK	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270967	rs4968187	TP53	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270973	rs181501757	TOP2A	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270979	rs142244113	INSR	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270985	rs41412545	INSR	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AC	Patients with breast cancer and the AC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270991	rs118129530	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449270997	rs56022120	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271003	rs117341846	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271009	rs117951771	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271015	rs148235907	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271021	rs138602176	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271027	rs150688309	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CG	Patients with breast cancer and the CG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271033	rs79430272	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271039	rs55633228	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271045	rs148013902	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271051	rs145623321	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271057	rs58695150	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271063	rs8110364	PIK3R2	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271069	rs74743371	CBR3	Toxicity	cyclophosphamide;epirubicin;fluorouracil	GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GT	Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271075	rs112783657	CBR3	Toxicity	cyclophosphamide;epirubicin;fluorouracil	CC	Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							CT	Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							TT	Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449271393	rs141084494	RBX1	Toxicity	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							AG	Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
							GG	Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.		
	3	1449577050	rs6151031	ALDH1A1	Efficacy	cyclophosphamide;doxorubicin	CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC	Patients with breast cancer and the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.		
							del/CTGGTGAGGAGAGAACC	Patients with breast cancer and the del/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.		
							del/del	Patients with breast cancer and the del/del genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del/CTGGTGAGGAGAGAACC or CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC genotypes (please note: the del/del genotype was not observed in this cohort). Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.		
	3	1449718242	rs1056836	CYP1B1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with the CC genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							CG	Patients with the CG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							GG	Patients with the GG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
	3	1449718248	rs2231142	ABCG2	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	GG	Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
							GT	Patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
							TT	No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
	3	1449718259	rs714368	SLC22A16	Efficacy;Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
							CT	Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
							TT	Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		
	3	1449718265	rs12248560	CYP2C19	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with the CC genotype and breast cancer may have an increased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.		
							CT	Patients with the CT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.		
							TT	Patients with the TT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.		
	3	1449718271	rs4244285	CYP2C19	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
							AG	Patients with AG genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
							GG	Patients with GG genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
	3	1449718277	rs2273697	ABCC2	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		
							AG	Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		
							GG	Patients with GG genotype and breast cancer may have an increased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		
	3	1449718283	rs3740066	ABCC2	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		
							CT	Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		
							TT	Patients with TT genotype and breast cancer may have an increased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		
	3	1449718289	rs1801516	ATM	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with AA genotype and breast cancer may have an increased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.		
							AG	Patients with AG genotype and breast cancer may have an increased risk of nausea as compared to the GG genotype, and a decreased risk of vomiting as compared to the AA genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.		
							GG	Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.		
	3	1449718300	rs2228100	ALDH3A1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with CC genotype and breast cancer may have a decreased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.		
							CG	Patients with CG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.		
							GG	Patients with GG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.		
	3	1449718311	rs3212986	ERCC1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
							AC	Patients with AC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
							CC	Patients with CC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.		
	3	1449718317	rs11615	ERCC1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.		
							AG	Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.		
							GG	Patients with GG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.		
	3	1449718323	rs20572	CBR1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with CC genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.		
							CT	Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.		
							TT	Patients with TT genotype and breast cancer may have an increased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.		
	3	1449718331	rs25487	XRCC1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	CC	Patients with the CC genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							CT	Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							TT	Patients with the TT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
	3	1449718337	rs1695	GSTP1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with the AA genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							AG	Patients with the AG genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
							GG	Patients with the GG genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.		
	3	1449718343	rs1045642	ABCB1	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	AA	Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
							AG	Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
							GG	Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		
	3	1451158880	rs36120609	GSTM3	Toxicity	cisplatin;cyclophosphamide	TC/TC	Patients with the TC/TC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.		
							TC/TCCTC	Patients with the TC/TCCTC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.		
							TCCTC/TCCTC	Patients with the TCCTC/TCCTC genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TC/TC or TC/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.s		
	3	1451398140	rs1695	GSTP1	Efficacy	cyclophosphamide;epirubicin	AA	Patients with breast cancer as the rs1695 AA genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.		
							AG	Patients with breast cancer as the rs1695 AG genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.		
							GG	Patients with breast cancer as the rs1695 GG genotype may have a decreased response to treatment with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.		
	3	1451398160	rs1695	GSTP1	Toxicity	cyclophosphamide;epirubicin	AA	Patients with breast cancer and the rs1695 AA genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.		
							AG	Patients with breast cancer and the rs1695 AG genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.		
							GG	Patients with breast cancer and the rs1695 GG genotype may experience an increased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.		
	3	1451398180	rs1695	GSTP1	Toxicity	cyclophosphamide;epirubicin	AA	Patients with breast cancer and the rs1695 AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.		
							AG	There is currently no available evidence regarding the association between the rs1695 AG genotype and risk of developing neutropenia when treated with cyclophosphamide and epirubicin. However, patients with breast cancer and the AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.		
							GG	Patients with breast cancer and the rs1695 GG genotype may be at a decreased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.		
	3	1451398300	rs1800566	NQO1	Efficacy	cyclophosphamide;epirubicin;fluorouracil	AA	Patients with breast cancer and the rs1800566 AA genotype may have a decreased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.		
							AG	Patients with breast cancer and the rs1800566 AG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.		
							GG	Patients with breast cancer and the rs1800566 GG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.		
	3	655384534	rs4880	SOD2	Efficacy	cyclophosphamide	AA	Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.		
							AG	Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.		
							GG	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.		
	3	655386801	rs3957357	GSTA1	Toxicity	cisplatin;cyclophosphamide	AA	Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.		
							AG	Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.		
							GG	Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.		
	3	655386990	rs2279343	CYP2B6	Toxicity	cyclophosphamide	AA	Patients with the AA genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.		
							AG	Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.		
							GG	Patients with the GG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.		
	3	655386995	rs2740574	CYP3A4	Toxicity	cyclophosphamide	CC	Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.		
							CT	Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.		
							TT	Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.		
	3	655386999	rs8192709	CYP2B6	Toxicity	cyclophosphamide	CC	Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.		
							CT	Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.		
							TT	Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.		
	3	655387004	rs9561778	ABCC4	Toxicity	cyclophosphamide	GG	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		
							GT	Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		
							TT	Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		
	3	655387009	rs1799983	NOS3	Efficacy	cyclophosphamide;doxorubicin;fluorouracil;methotrexate	GG	Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.		
							GT	Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.		
							TT	Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.		
	3	655387014	rs2070744	NOS3	Efficacy	cyclophosphamide;doxorubicin;fluorouracil;methotrexate	CC	Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.		
							CT	Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.		
							TT	Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.		
	3	827848548	rs9561778	ABCC4	Toxicity	cyclophosphamide;doxorubicin;fluorouracil	GG	Patients with the GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.		
							GT	Patients with the GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.		
							TT	Patients with the TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for ADRs.		
	3	981202334	rs3745274	CYP2B6	Toxicity	cyclophosphamide	GG	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.		
							GT	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.		
							TT	Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.		
	3	981202356	rs3745274	CYP2B6	Dosage	cyclophosphamide;doxorubicin	GG	Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.		
							GT	Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.		
							TT	Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.		
	3	981202551	rs4244285	CYP2C19	Efficacy	cyclophosphamide;doxorubicin	AA	Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							AG	Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							GG	Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
	3	981202562	rs4244285	CYP2C19	Toxicity	cyclophosphamide	AA	Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.		
							AG	Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.		
							GG	Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.		
	3	981237930	rs11615	ERCC1	Toxicity	cisplatin;cyclophosphamide	AA	Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result		
							AG	Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.		
							GG	Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.		
	3	981237950	rs1695	GSTP1	Efficacy	cisplatin;cyclophosphamide	AA	Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.		
							AG	Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.		
							GG	Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.		
	3	981238025	rs2032582	ABCB1	Efficacy	cyclophosphamide;doxorubicin	CC	Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		
							CT	Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		
							TT	Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		
	3	981238323	rs1695	GSTP1	Efficacy	cyclophosphamide	AA	Patients with the rs1695 AA genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.		
							AG	Patients with the rs1695 AG genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.		
							GG	Patients with the rs1695 GG genotype and Neoplasms may have decreased response to cyclophosphamide as compared to patients with AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.		
	3	982036556	rs4148416	ABCC3	Efficacy	cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine	CC	Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.		
							CT	Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		
							TT	Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.		
	3	982036595	rs4148737	ABCB1	Efficacy	cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine	CC	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		
							CT	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		
							TT	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		
	3	982036604	rs1128503	ABCB1	Efficacy	cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine	AA	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		
							AG	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		
							GG	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		
免疫抑制剂|环孢霉素|cyclosporine	3	1043880066	rs1800872	IL10	Efficacy	cyclosporine;mycophenolate mofetil	GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							GT	Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							TT	Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
	3	1043880077	rs1800629	TNF	Efficacy	cyclosporine;mycophenolate mofetil	AA	Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							AG	Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
	3	1043880082	rs1042597	UGT1A8	Toxicity	cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							CG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							GG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
	3	1183698786	rs28371759	CYP3A4	Other	cyclosporine	AA	Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.		
							AG	Patients with the AG genotype (CYP3A4 *1/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.		
							GG	Patients with the GG genotype (CYP3A4 *18B/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1/*1 or *1/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.		
	3	1184986481	rs35599367	CYP3A4	Other	cyclosporine	AA	Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.		
							AG	Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.		
							GG	Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.		
	3	1444673163	rs1057868	POR	Metabolism/PK	cyclosporine	CC	Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.		
							CT	Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.		
							TT	Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.		
	3	1444686907	rs4646437	CYP3A4	Efficacy;Metabolism/PK	cyclosporine	AA	Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.		
							AG	Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.		
							GG	Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.		
	3	1444694373	rs7903146	TCF7L2	Toxicity	cyclosporine;sirolimus;tacrolimus	CC	Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
							CT	Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
							TT	Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
	3	1446899616	rs776746	CYP3A5	Dosage;Metabolism/PK	cyclosporine	CC	Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.		
							CT	Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype who is also a CYP3A4 low or intermediate expresser. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.		
							TT	Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.		
	3	1447963004	rs2032582	ABCB1	Metabolism/PK	cyclosporine;dicloxacillin	AA	Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		
							AC	Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		
							CC	Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		
	3	1448100110	rs231775	CTLA4	Toxicity	cyclosporine	AA	Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.		
							AG	Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.		
							GG	Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.		
	3	1448605477	rs8450	CRTC2	Toxicity	cyclosporine;tacrolimus	AA	Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT.		
							AG	Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT.		
							GG	Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT.		
	3	1448634742	rs717620	ABCC2	Metabolism/PK	cyclosporine;mycophenolic acid	CC	Patients with the CC genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the CT and TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
							CT	Patients with the CT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CC genotype, and decreased exposure compared to patients with the TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
							TT	Patients with the TT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CT and CC genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
	3	1448634752	rs2273697	ABCC2	Metabolism/PK	cyclosporine;mycophenolic acid	AA	Patients with the AA genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the AG and GG genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
							AG	Patients with the AG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the GG genotype, and increased exposure as compared to patients with the AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
							GG	Patients with the GG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the AG and AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.		
	3	1449005066	rs2740574	CYP3A;CYP3A4	Toxicity	cyclosporine;tacrolimus	CT	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B) may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.		
							TT	Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.		
	3	1449165704	CYP3A5*1, CYP3A5*3	CYP3A5	Metabolism/PK	cyclosporine	*1	Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have decreased metabolism of cyclosporine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.	Normal function	
							*3	Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have increased metabolism of cyclosporine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.	No function	
	3	1450935200	rs2740574	CYP3A4	Metabolism/PK	cyclosporine	CC	Patients with the rs2740574 CC genotype and who are treated with cyclosporine following kidney transplantation may have decreased blood concentrations of cyclosporine as compared to patients with the rs2740574 CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.		
							CT	Patients with the rs2740574 CT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.		
							TT	Patients with the rs2740574 TT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.		
	3	1450944540	rs1128503	ABCB1	Toxicity	cyclosporine	AA	Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		
							AG	Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		
							GG	Patients with the GG genotype may be at an increased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the AA or AG genotypes. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		
	3	655384539	rs2032582	ABCB1	Efficacy	cyclosporine	AA	Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.		
							AC	Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.		
							CC	Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.		
	3	655384546	rs1128503	ABCB1	Dosage	cyclosporine	AA	Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		
							AG	Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		
							GG	Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		
	3	655387053	CYP3A5*1, CYP3A5*3	CYP3A5	Dosage	cyclosporine	*1	Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have increased cyclosporine dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.	Normal function	
							*3	Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have decreased cyclosporine dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.	No function	
	3	827831435	rs2032582	ABCB1	Dosage	cyclosporine	AA	Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		
							AC	Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		
							CC	Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		
							CT	Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		
	3	981204286	rs1045642	ABCB1	Metabolism/PK	cyclosporine	AA	Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.		
							AG	Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.		
							GG	Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.		
	3	982040619	rs2032582	ABCB1	Efficacy	cyclosporine;mycophenolate mofetil	AA	Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							AC	Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							CC	Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
免疫抑制剂|地塞米松|Dexamethasone	3	1043880851	rs4553808	CTLA4	Toxicity	bortezomib;dexamethasone;melphalan;prednisone	AA	Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
							AG	Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
							GG	Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
	3	1184512128	rs3824662	GATA3	Efficacy	asparaginase;cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;leucovorin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							AC	Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							CC	Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
	3	1447953328	rs4135385	CTNNB1	Efficacy;Toxicity	cyclophosphamide;dexamethasone;lenalidomide;thalidomide	AA	Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							AG	Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							GG	Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
	3	1447963255	rs7142143	PYGL	Efficacy	asparaginase;dexamethasone;methotrexate	CC	Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.		
							CT	Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.		
							TT	Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse.		
	3	1448098793	rs17021408		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099059	rs1891059		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099093	rs117532069	DOK5	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099112	rs79085477	BMP7	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099135	rs141059755	LINC00251	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099430	rs80223967		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							AG	Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							GG	Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
	3	1448100249	rs6092	SERPINE1	Toxicity	dexamethasone	AA	Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.		
							AG	Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.		
							GG	Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.		
	3	1449170621	rs2229109	ABCB1	Efficacy	dexamethasone;lenalidomide	CC	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		
							CT	Patients with the CT genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have longer of progression-free survival as compared to patients with the CC genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		
	3	981204433	rs1045642	ABCB1	Efficacy	dexamethasone;doxorubicin;vincristine	AA	Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		
							AG	Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		
							GG	Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		
	3	981238041	rs2032582	ABCB1	Efficacy	dexamethasone;doxorubicin;vincristine	AA	Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		
							AC	Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		
							CC	Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		
高血压药|依那普利|Enalapril	3	1183614845	rs1042714	ADRB2	Efficacy	enalapril	CC	Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.		
							CG	Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.		
							GG	Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.		
	3	1184233161	rs5522	NR3C2	Efficacy	enalapril	CC	Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
							CT	Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
							TT	Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
	3	1444700999	rs1799722	BDKRB2	Efficacy	enalapril	CC	Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.		
							CT	Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.		
							TT	Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.		
	3	1444701007	rs1799722	BDKRB2	Toxicity	enalapril;imidapril;lisinopril	CC	Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
							CT	Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
							TT	Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
	3	1444703951	rs495828		Toxicity	enalapril	GG	Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
							GT	Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
							TT	Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.		
	3	1446899476	rs71647871	CES1	Metabolism/PK	enalapril	CC	Patients with the rs71647871 CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.		
							CT	Patients with the rs71647871 CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.		
							TT	There is currently no available evidence regarding the association between the rs71647871 TT genotype and metabolism of enalapril. However, patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.		
	3	1447953130	rs4149056	SLCO1B1	Toxicity	enalapril	CC	Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		
							CT	Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		
							TT	Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		
	3	1447960484	rs2070744	NOS3	Efficacy	enalapril	CC	Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.		
							CT	Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.		
							TT	Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.		
	3	1447990902	rs699947	VEGFA	Efficacy	enalapril	AA	Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.		
							AC	Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.		
							CC	Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.		
生物制剂|依那西普|Etanercept	2B	655384799	rs1800629	TNF	Efficacy	etanercept	AA	Patients with the rs1800629 AA genotype may have decreased response to etanercept as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence response to etanercept.		
							AG	Patients with the rs1800629 AG genotype may have increased response to etanercept as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept.		
							GG	Patients with the rs1800629 GG genotype may have increased response to etanercept as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to etanercept.		
降尿酸药|非布司他|Febuxostat	3	1448428918	rs34650714	UGT1A1;UGT1A10;UGT1A3;UGT1A4;UGT1A5;UGT1A6;UGT1A7;UGT1A8;UGT1A9	Dosage	allopurinol;febuxostat	CC	Patients with the CC genotype and gout may require a dose of 300 mg/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
							CT	Patients with the CT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
							TT	Patients with the TT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.		
	3	1448428937	rs75995567	AOX1	Dosage	allopurinol;febuxostat	CC	Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							CT	Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							TT	Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
	3	1448428944	rs3731722	AOX1	Dosage	allopurinol;febuxostat	AA	Patients with the AA genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							AG	Patients with the AG genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
							GG	Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.		
高血压药|非洛地平|felodipine	3	1183605989	rs2239128	CACNA1C	Efficacy	calcium channel blockers	CC	Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		
							CT	Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.		
							TT	Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		
	3	1183606395	rs2239050	CACNA1C	Efficacy	calcium channel blockers	CC	Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		
							CG	Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.		
							GG	Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.		
	3	1183606758	rs2238032	CACNA1C	Efficacy	calcium channel blockers	GG	Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.		
							GT	Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.		
							TT	Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.		
	3	1446906412	rs2429427	TANC2	Efficacy	calcium channel blockers	AA	Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.		
							AG	Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.		
							GG	Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.		
	3	1448099065	rs10898815	NUMA1	Efficacy	calcium channel blockers	AA	Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
							AG	Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
							GG	Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
	3	1448099080	rs588076	PICALM	Efficacy	calcium channel blockers	CC	Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
							CG	Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
							GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.		
	3	982009415	rs1137617	KCNH2	Efficacy	calcium channel blockers;nitrendipine	AA	Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.		
							AG	Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.		
							GG	Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.		
非甾体抗炎药|氟比洛芬|Flurbiprofen	1A	1444842106	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*29	CYP2C9	Metabolism/PK	flurbiprofen	*1	The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.	Normal function	
							*2	The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.	Decreased function	
							*29	The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*29 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.	Decreased function	
							*3	The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.	No function	
降脂药|氟伐他汀|Fluvastatin	3	1043880409	rs60282872	SREBF1	Efficacy	fluvastatin	C/del	Patients with the CC/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels as compared to patients with the C/C genotype, or may have a larger change in apolipoprotein A1 and C3 levels as compared to patients with the del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							CC	Patients with the CC genotype who are treated with fluvastatin may have a larger change in apolipoprotein A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							del/del	Patients with the del/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels, as compared to patients with the CC or C/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
	3	1045153881	rs1057910	CYP2C9	Other	fluvastatin	AA	Patients with the AA (CYP2C9*1/*1) genotype may have lower plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or CC (CYP2C9*3/*3) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.		
							AC	Patients with the AC (CYP2C9*1/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.		
							CC	Patients with the CC (CYP2C9*3/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.		
	3	1156076089	rs2231142	ABCG2	Other	fluvastatin	GG	Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.		
							GT	Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.		
							TT	Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin.		
	3	1183491359	rs4783961	CETP	Efficacy	fluvastatin	AA	Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							AG	Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							GG	Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
	3	1183491380	rs1922242	ABCB1	Efficacy	fluvastatin	AA	Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							AT	Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							TT	Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
	3	1183491385	rs5882	CETP	Efficacy	fluvastatin	AA	Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							AG	Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
							GG	Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		
	3	1183492128	rs7412	APOE	Efficacy	fluvastatin	CC	Patients with the CC genotype who are treated with fluvastatin may have a reduced response (a smaller reduction in LDL-cholesterol or change in HDL) as compared to patients with the CT genotype (carriers of E2). Other genetic and clinical factors may also influence a patient's response to statin treatment.		
							CT	Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.		
							TT	Patients with the TT genotype (also known as E2/E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype, although the studies did not have C homozygotes and only reported the effect for the heterozygote. Other genetic and clinical factors may also influence a patient's response to statin treatment.		
	3	1184749403	SLCO1B1*1, SLCO1B1*14	SLCO1B1	Efficacy	fluvastatin	*1	Patients with the *1 allele in combination with another normal function allele may have decreased lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *14/*14 genotype. Other genetic and clinical factors may also influence response to fluvastatin.	Normal function	
							*14	Patients with the *14 allele in combination with a *14 or *1 allele may have enhanced lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence response to fluvastatin.	Increased function	
	3	1447962703	rs4986910	CYP3A4	Efficacy	fluvastatin	AA	Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
							AG	Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
							GG	No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
	3	1447962710	rs1800588	LIPC	Efficacy	fluvastatin;simvastatin	CC	Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
							CT	Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
							TT	Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.		
	3	1451244700	rs4149056	SLCO1B1	Metabolism/PK	fluvastatin	CC	Patients with the CC genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
							CT	Patients with the CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
							TT	Patients with the TT genotype may have decreased concentrations of fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
	3	1451244720	rs4149056	SLCO1B1	Toxicity	fluvastatin	CC	Patients with the CC genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
							CT	Patients with the CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
							TT	Patients with the TT genotype may have a decreased risk of developing myopathy when treated with fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable.”		
	3	1451409127	CYP2D6*1, CYP2D6*4	CYP2D6	Efficacy	fluvastatin	*1	Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have a decreased response to fluvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to fluvastatin.	Normal function	
							*4	Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have an increased response to fluvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to fluvastatin.	No function	
	3	655384582	rs11045819	SLCO1B1	Efficacy	fluvastatin	AA	Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.		
							AC	Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.		
							CC	Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.		
	3	655384616	rs17238540	HMGCR	Efficacy	atorvastatin;fluvastatin;hmg coa reductase inhibitors;lovastatin;pravastatin;simvastatin	GG	Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
							GT	Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
							TT	Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
利尿剂|呋塞米|Furosemide	3	1183563324	rs5443	GNB3	Efficacy	bumetanide;furosemide;torasemide	CC	Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
							CT	Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
							TT	Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
	3	1183589777	rs4961	ADD1	Efficacy	bumetanide;furosemide;torasemide	GG	Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
							GT	Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
							TT	Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.		
	3	1183698808	rs5063	NPPA-AS1	Efficacy	bumetanide;furosemide;torasemide	CC	Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs.		
							CT	Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.		
							TT	Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.		
	3	1444673002	rs1529927	SLC12A3	Efficacy	bumetanide;furosemide;torasemide	CC	Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics.		
							CG	Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		
							GG	Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		
	3	1448424039	rs17268282	ABCC4	Efficacy	furosemide	GG	Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.		
							GT	Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.		
							TT	Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.		
	3	981202806	rs4961	ADD1	Efficacy	furosemide;spironolactone	GG	Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
							GT	Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
							TT	Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
利尿剂|氢氯噻嗪|Hydrochlorothiazide	2B	981202714	rs4961	ADD1	Efficacy	hydrochlorothiazide	GG	Patients with the rs4961 GG genotype may have decreased response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.		
							GT	Patients with the rs4961 GT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.		
							TT	Patients with the rs4961 TT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.		
非甾体抗炎药|布洛芬|Ibuprofen	1A	1451092720	CYP2C9*1, CYP2C9*2, CYP2C9*3	CYP2C9	Metabolism/PK	ibuprofen	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.	Normal function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased allele, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.	No function	
高血压药|咪达普利|Imidapril	3	1183614605	rs1799998	CYP11B2	Efficacy	benazepril;imidapril	AA	Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
							AG	Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
							GG	Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.		
	3	1444666376	rs5051	AGT	Efficacy	benazepril;imidapril	CC	Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
							CT	Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
							TT	Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.		
	3	1444701007	rs1799722	BDKRB2	Toxicity	enalapril;imidapril;lisinopril	CC	Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
							CT	Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
							TT	Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.		
生物制剂|英夫利昔单抗|Infliximab	3	1183615424	rs767455	TNFRSF1A	Efficacy	adalimumab;etanercept;infliximab	CC	Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
							CT	Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
							TT	Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.		
	3	1183700527	rs10919563	PTPRC	Efficacy	adalimumab;etanercept;infliximab;Tumor necrosis factor alpha (TNF-alpha) inhibitors	AA	Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
							AG	Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
							GG	Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.		
	3	1184169936	rs1801274	FCGR2A	Efficacy	adalimumab;infliximab	AA	Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							GA	Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							GG	Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.		
	3	1444673156	rs396991	FCGR3A	Efficacy	adalimumab;etanercept;infliximab	AA	Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
							AC	Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
							CC	Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.		
	3	1444702664	rs3761847	TRAF1	Efficacy	adalimumab;etanercept;infliximab;Tumor necrosis factor alpha (TNF-alpha) inhibitors	AA	Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
							AG	Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
							GG	Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.		
	3	1444703171	rs1800795	IL6	Efficacy	adalimumab;etanercept;infliximab	CC	Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
							CG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
							GG	Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.		
	3	1444704321	rs1061622	TNFRSF1B	Efficacy	infliximab;Tumor necrosis factor alpha (TNF-alpha) inhibitors	GG	Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.		
							GT	Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.		
							TT	Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.		
	3	1447945887	rs396991	FCGR3A	Efficacy	infliximab	AA	Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							AC	Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.		
							CC	Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.		
	3	1447946124	rs361525	TNF	Efficacy	infliximab	AA	No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.		
							AG	Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.		
							GG	Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.		
	3	1447952819	rs1059150	ATP5F1E	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	GG	Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							GT	Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							TT	Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
	3	1447952831	rs1264457	HLA-E	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	AA	Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							AG	Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
							GG	Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.		
	3	1447960309	rs1143634	IL1B	Efficacy	infliximab	AA	Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.		
							AG	Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.		
							GG	Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.		
	3	1448266599	rs2302489	KLRD1	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	AA	Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.		
							AT	Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.		
							TT	Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.		
	3	1448266609	rs7301582	KLRC1	Efficacy	adalimumab;certolizumab pegol;etanercept;glucocorticoids;infliximab;methotrexate	CC	Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
							CT	Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
							TT	Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.		
高血压药|厄贝沙坦|Irbesartan	3	1183564259	rs5370	EDN1	Efficacy	atenolol;irbesartan	GG	Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
							GT	Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
							TT	No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.		
	3	1183614481	rs1801701	APOB	Efficacy	irbesartan	CC	Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.		
							CT	Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.		
							TT	Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.		
	3	1183615573	rs699	AGT	Efficacy	irbesartan	AA	Patients with the rs699 AA genotype may have a decreased response to irbesartan as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							AG	Patients with the rs699 AG genotype may have an increased response to irbesartan as compared to patients with the AA genotype, but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							GG	Patients with the rs699 GG genotype may have an increased response to irbesartan as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
	3	1447990044	rs1799853	CYP2C9	Efficacy	irbesartan	CC	Patients with the CC genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.		
							CT	Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.		
	3	1447990143	rs1057910	CYP2C9	Efficacy;Metabolism/PK	irbesartan	AA	Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.		
							AC	Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.		
	3	1447990235	rs72558187	CYP2C9	Metabolism/PK	irbesartan	CT	Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.		
							TT	Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.		
	3	1451493592	rs4762	AGT	Efficacy	irbesartan	AA	There is currently no available evidence regarding the association between the rs4762 AA genotype and response to irbesartan. However, patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							AG	Patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							GG	Patients with the rs4762 GG genotype may have a decreased response to irbesartan as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
	3	1451493693	rs5186	AGTR1	Efficacy	irbesartan	AA	Patients with the rs5186 AA genotype may have a decreased response to irbesartan as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							AC	Patients with the rs5186 AC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
							CC	Patients with the rs5186 CC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.		
	3	655385369	rs1367117	APOB	Efficacy	irbesartan	AA	Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response.		
							AG	Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		
							GG	Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		
消化道相关|兰索拉唑|lansoprazole	1A	1183629796	CYP2C19*1, CYP2C19*2, CYP2C19*3	CYP2C19	Efficacy	lansoprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to lansoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, poorer healing or cure rate of gastroesophageal reflux disease, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.	Normal function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.	No function	
	1A	1450806874	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9, CYP2C19*17	CYP2C19	Metabolism/PK	lansoprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of lansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of lansoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	Normal function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of lansoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	No function	
							*8	The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	No function	
							*9	The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.	Decreased function	
免疫抑制剂|来氟米特|Leflunomide	3	1447979272	rs2234693	ESR1	Efficacy	leflunomide	CC	Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.		
							CT	Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.		
							TT	Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.		
	3	655384906	rs3213422	DHODH	Efficacy	leflunomide	AA	Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.		
							AC	It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.		
							CC	Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		
	3	827848740	rs9340799	ESR1	Efficacy	leflunomide	AA	Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.		
							AG	Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.		
							GG	Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.		
高血压药|氯沙坦|losartan	3	1143918642	rs12721226	AGTR1	Efficacy	losartan	AA	Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.		
							AG	The AG genotype was not studied in association with affinity to losartan.		
							GG	Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.		
	3	1183615090	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*13, CYP2C9*59, CYP2C9*62	CYP2C9	Metabolism/PK	losartan	*1	Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	Normal function	
							*13	Patients carrying the CYP2C9*13 allele in combination with a normal function allele (e.g. *1/*13) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	No function	
							*2	Patients carrying the CYP2C9*2 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 2 allele in combination with a normal function allele (e.g. *1/*2) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	Decreased function	
							*3	Patients carrying the CYP2C9*3 allele in combination with a normal function allele (e.g. *1/*3) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	No function	
							*5	Patients carrying the CYP2C9*5 allele in combination with a normal function allele (e.g. *1/*5) or another decreased function allele (e.g.*5/*8) or a no function allele (e.g. *5/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	Decreased function	
							*59	Patients carrying the CYP2C9*59 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	Uncertain function	
							*6	Patients carrying the CYP2C9*6 allele in combination with a normal function allele (e.g. *1/*6) or a decreased function allele (e.g. *5/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	No function	
							*62	Patients carrying the CYP2C9*62 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. CPIC has not yet assigned a functional status to this allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.		
							*8	Patients carrying the CYP2C9*8 allele in combination with another decreased function allele (e.g. *5/*8) may have decreased metabolism of losartan as compared to patients with two normal function alleles. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 8 allele in combination with a normal function (e.g. *1/*8) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.	Decreased function	
	3	1183697278	rs1934969	CYP2C9	Other	losartan	AA	Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.		
							AT	Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.		
							TT	Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.		
	3	1183704372	rs6749447	STK39	Efficacy	losartan	GG	Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.		
							GT	Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.		
							TT	Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.		
	3	1445401296	rs10752271	CAMK1D	Toxicity	losartan	AA	Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.		
							AG	Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.		
							GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.		
	3	1445401303	rs10737062	CAMK1D	Toxicity	losartan	AA	Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.		
							AG	Patients with the AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.		
							GG	Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.		
	3	1447960623	rs5186	AGTR1	Efficacy	losartan	AA	Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.		
							AC	Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.		
							CC	Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.		
	3	1447960656	rs5186	AGTR1	Efficacy	losartan	AA	Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.		
							AC	Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.		
							CC	Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.		
	3	1448100521	rs3814995	NPHS1	Efficacy	losartan	CC	Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.		
							CT	Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.		
							TT	Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.		
	3	1448123001	rs1045642	ABCB1	Efficacy	losartan	AA	Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.		
							AG	Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.		
							GG	Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.		
	3	981238459	rs1057910	CYP2C9	Efficacy	losartan	AA	Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.		
							AC	Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.		
							CC	Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.		
降脂药|洛伐他汀|Lovastatin	3	1043880205	rs708272	CETP	Efficacy	lovastatin	AA	Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.		
							AG	Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.		
							GG	Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.		
	3	1183491157	rs776746	CYP3A5	Efficacy	lovastatin	CC	Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.		
							CT	Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.		
							TT	Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.		
	3	1183492035	rs662799	APOA5	Efficacy	atorvastatin;lovastatin;simvastatin	AA	Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.		
							AG	Patients with the rs662799 AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.		
							GG	Patients with the rs662799 GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.		
	3	1183697388	CYP2D6*1, CYP2D6*5, CYP2D6*10	CYP2D6	Other	lovastatin	*1/*1	Patients with the *1/*1 genotype may have increased metabolism of lovastatin as compared to patients carrying the *5 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.		
							*1/*10	Patients with the *1/*10 genotype may have decreased metabolism of lovastatin as compared to patients with the *1/*1 genotype, but increased metabolism of lovastatin as compared to patients with the *10/*10 genotype or who are carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.		
							*10/*10	Patients with the *10/*10 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 allele, but increased metabolism of lovastatin as compared to patients carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.		
	3	1444706164	rs2291073	SLCO1B1	Efficacy	lovastatin	GG	Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.		
							TG	Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.		
							TT	Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.		
	3	1447962737	rs688	LDLR	Efficacy	lovastatin	CC	Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
							CT	Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
							TT	Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
	3	1447962744	rs5925	LDLR	Efficacy	lovastatin	CC	Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
							CT	Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
							TT	Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.		
	3	1451465324	rs4149056	SLCO1B1	Toxicity	lovastatin	CC	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CC genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.		
							CT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.		
							TT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 TT genotype may have a decreased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.		
	3	655384616	rs17238540	HMGCR	Efficacy	atorvastatin;fluvastatin;hmg coa reductase inhibitors;lovastatin;pravastatin;simvastatin	GG	Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
							GT	Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
							TT	Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.		
免疫抑制剂|巯嘌呤|Mercaptopurine	1A	1184648909	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*4, TPMT*9, TPMT*12	TPMT	Toxicity	mercaptopurine	*1	The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	Normal function	
							*12	The TPMT*12 allele is assigned as a no function allele by DPWG. Patients with the *12 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*12 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.	Uncertain function	
							*2	The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	No function	
							*3A	The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	No function	
							*3B	The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	No function	
							*3C	The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	No function	
							*4	The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.	No function	
							*9	The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the *9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.	Uncertain function	
	1A	1448635217	NUDT15*1, NUDT15*2, NUDT15*3	NUDT15	Dosage	mercaptopurine	*1	The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.	Normal function	
							*2	The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*2 allele in combination with a normal function or no function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.	No function	
							*3	The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*3 allele in combination with another no function may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.	No function	
	1A	1451237200	TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*9	TPMT	Dosage	mercaptopurine	*1	The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.	Normal function	
							*2	The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.	No function	
							*3A	The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.	No function	
							*3B	The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.	No function	
							*3C	The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.	No function	
							*9	The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the TPMT*9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine dosage.	Uncertain function	
	1A	1451290840	rs116855232	NUDT15	Dosage	mercaptopurine	CC	Patients with the rs116855232 CC genotype may have increased dose of mercaptopurine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence mercaptopurine dose.		
							CT	Patients with the rs116855232 CT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.		
							TT	Patients with the rs116855232 TT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.		
	1A	1451448820	NUDT15*1, NUDT15*2, NUDT15*3	NUDT15	Toxicity	mercaptopurine	*1	The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.	Normal function	
							*2	The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients with the *2 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.	No function	
							*3	The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients with the *3 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.	No function	
免疫抑制剂|甲氨蝶呤|Methotrexate	2A	1451245360	rs1051266	SLC19A1	Efficacy	methotrexate	CC	Patients with the rs1051266 CC genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		
							CT	Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		
							TT	Patients with the rs1051266 TT genotype and rheumatoid arthritis may have increased response when treated with methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		
	2A	1451504901	rs1801133	MTHFR	Metabolism/PK	methotrexate	AA	Patients with the rs1801133 AA genotype may have increased concentrations of methotrexate as compared to the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mehtotrexate concentrations.		
							AG	Patients with the rs1801133 AG genotype may have increased concentrations of methotrexate as compared to the GG genotype but decreased concentrations as compared to the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mehtotrexate concentrations.		
							GG	Patients with the rs1801133 GG genotype may have decreased concentrations of methotrexate as compared to the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mehtotrexate concentrations.		
	2A	655385307	rs1801133	MTHFR	Toxicity	methotrexate	AA	Patients with the rs1801133 AA genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity.		
							AG	Patients with the rs1801133 AG genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or may have a decreased risk of adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity.		
							GG	Patients with the rs1801133 GG genotype and Arthritis who are treated with methotrexate may have a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity.		
	2A	827848365	rs1801133	MTHFR	Toxicity	methotrexate	AA	Patients with the rs1801133 AA genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment.		
							AG	Patients with the rs1801133 AG genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the GG genotype, and may be at decreased risk of toxicity compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment.		
							GG	Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment.		
	2B	981202609	rs4673993	ATIC	Efficacy	methotrexate	CC	Patients with the rs4673993 CC genotype and Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate response.		
							CT	Patients with the rs4673993 CT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.		
							TT	Patients with the rs4673993 TT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.		
高血压药|美托洛尔|Metoprolol	1A	1447681932	CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*31, CYP2D6*35, CYP2D6*41	CYP2D6	Metabolism/PK	metoprolol	*1	The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Normal function	
							*10	The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Decreased function (AV 0.25)	
							*17	The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Decreased function	
							*2	The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Normal function	
							*29	The CYP2D6*29 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *29 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *29 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Decreased function	
							*3	The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	No function	
							*31	The CYP2D6*31 allele has been assigned as a no function allele by CPIC. Patients carrying the *31 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *31 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *31 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	No function	
							*35	The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Normal function	
							*4	The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	No function	
							*41	The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Decreased function	
							*6	The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	No function	
							*9	The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.	Decreased function	
	1A	1450415170	CYP2D6*1, CYP2D6*4	CYP2D6	Dosage	metoprolol	*1	The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may require a decreased dose of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also require a decreased dose of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but an increased dose as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence metoprolol dose requirements.	Normal function	
							*4	The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may require a decreased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may require a similar dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may require an increased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metoprolol dose requirements.	No function	
免疫抑制剂|米托蒽醌|Mitoxantrone	3	1448099568	rs2291075	SLCO1B1	Efficacy	cytarabine;daunorubicin;etoposide;mitoxantrone	CC	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
							CT	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
							TT	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
	3	1448099574	rs2291075	SLCO1B1	Efficacy	cytarabine;daunorubicin;etoposide;mitoxantrone	CC	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
							CT	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
							TT	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		
	3	1448099784	rs12613732	GALNT14	Efficacy	cisplatin;fluorouracil;mitoxantrone	GG	Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.		
							GT	Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.		
							TT	Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.		
	3	1451124808	rs6025211		Efficacy	cisplatin;fluorouracil;mitoxantrone	CC	Patients with liver cancer and the CC genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.		
							CT	Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.		
							TT	Patients with liver cancer and the TT genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.		
	3	827847744	rs9679162	GALNT14	Efficacy	cisplatin;fluorouracil;mitoxantrone	GG	Patients with the rs9679162 GG genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.		
							GT	Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.		
							TT	Patients with the rs9679162 TT genotype and Liver Neoplasms may increased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.		
免疫抑制剂|霉酚酸酯（吗替麦考酚酯）|mycophenolate mofetil	3	1043859386	rs72551330	UGT1A9	Toxicity	mycophenolate mofetil	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.		
							CT	Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.		
							TT	Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.		
	3	1043880059	rs3832043	UGT1A9	Other	mycophenolate mofetil	DEL/DEL	Patients with the DEL/DEL genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/T and TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.		
							DEL/T	Patients with the DEL/T genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.		
							TT	Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.		
	3	1043880066	rs1800872	IL10	Efficacy	cyclosporine;mycophenolate mofetil	GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							GT	Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							TT	Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
	3	1043880077	rs1800629	TNF	Efficacy	cyclosporine;mycophenolate mofetil	AA	Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							AG	Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
							GG	Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.		
	3	1043880082	rs1042597	UGT1A8	Toxicity	cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							CG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							GG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
	3	1043880098	rs7311358	SLCO1B3	Other	mycophenolate mofetil	AA	Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							AG	Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							GG	Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
	3	1444607782	rs4149056	SLCO1B1	Toxicity	mycophenolate mofetil	CC	Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		
							CT	Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		
							TT	Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		
	3	1444607863	rs11572076	CYP2C8	Toxicity	mycophenolate mofetil	CC	Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.		
							CT	Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.		
							TT	Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.		
	3	1444703552	rs7438135	UGT2B7	Toxicity	mycophenolate mofetil	AA	Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							AG	Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							GG	Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
	3	1448101073	rs2228075	IMPDH1	Toxicity	mycophenolate mofetil	CC	Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.		
							CT	Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.		
							TT	Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.		
	3	981201408	rs2278294	IMPDH1	Efficacy	mycophenolate mofetil	CC	Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
							CT	Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
							TT	Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
	3	981201424	rs2278294	IMPDH1	Toxicity	mycophenolate mofetil	CC	Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
							CT	Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
							TT	Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		
	3	981201770	rs4149117	SLCO1B3	Dosage;Toxicity	mycophenolate mofetil	GG	Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.		
							GT	Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.		
							TT	Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.		
	3	982031795	rs568408	IL12A	Toxicity	mycophenolate mofetil	AA	Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.		
							AG	Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.		
							GG	Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.		
	3	982040619	rs2032582	ABCB1	Efficacy	cyclosporine;mycophenolate mofetil	AA	Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							AC	Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
							CC	Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		
非甾体抗炎药|萘普生|Naproxen	3	1451148780	rs780801862	CYP2C9	Metabolism/PK	naproxen	AA	Patients with the AA genotype may have increased metabolism of naproxen as compared to patients with the AT or TT genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.		
							AT	Patients with the AT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.		
							TT	Patients with the TT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.		
高血压药|尼群地平|Nitrendipine	3	1447960599	rs5186	AGTR1	Efficacy	nitrendipine	AA	Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.		
							AC	Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.		
							CC	Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.		
消化道相关|奥美拉唑|Omeprazole	1A	1183630036	CYP2C19*1, CYP2C19*2, CYP2C19*3	CYP2C19	Efficacy	omeprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to omeprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.	Normal function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.	No function	
	1A	1183630065	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*9, CYP2C19*10, CYP2C19*17, CYP2C19*24, CYP2C19*26	CYP2C19	Metabolism/PK	omeprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of omeprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of omeprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	Normal function	
							*10	The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	Decreased function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of omeprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	No function	
							*24	The CYP2C19*24 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*24 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	No function	
							*26	The CYP2C19*26 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	Decreased function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	No function	
							*9	The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.	Decreased function	
消化道相关|昂丹司琼|Ondansetron	1A	982014094	CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35xN	CYP2D6	Efficacy	ondansetron	*1	The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.	Normal function	
							*10	The CYP2C6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.	Decreased function (AV 0.25)	
							*2	The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.	Normal function	
							*4	The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.	No function	
消化道相关|泮托拉唑|Pantoprazole	1A	1183624491	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	CYP2C19	Metabolism/PK	pantoprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of pantoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of pantoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.	Normal function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of pantoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.	No function	
	1A	1183624499	CYP2C19*1, CYP2C19*2, CYP2C19*3	CYP2C19	Efficacy	pantoprazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to pantoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.	Normal function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.	No function	
高血压药|培哚普利|Perindopril	3	1447960649	rs5186	AGTR1	Efficacy	perindopril	AA	Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.		
							AC	Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.		
							CC	Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.		
	3	652472012	rs12050217	BDKRB1	Efficacy	perindopril	AA	Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.		
							AG	Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.		
							GG	Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.		
	3	652509715	rs275651	AGTR1	Efficacy	perindopril	AA	Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.		
							AT	Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.		
							TT	Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.		
	3	652519736	rs5182	AGTR1	Efficacy	perindopril	CC	Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		
							CT	Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		
							TT	Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		
非甾体抗炎药|吡罗昔康|Piroxicam	1A	1451092541	CYP2C9*1, CYP2C9*2, CYP2C9*3	CYP2C9	Metabolism/PK	piroxicam	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.	Normal function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.	No function	
降脂药|匹伐他汀|Pitavastatin	3	1043880567	rs2306283	SLCO1B1	Other	pitavastatin	AA	Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		
							AG	Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		
							GG	Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		
	3	1450814813	SLCO1B1*1, SLCO1B1*15	SLCO1B1	Metabolism/PK	pitavastatin	*1/*1	Patients with the *1/*1 genotype may have decreased exposure to pitavastatin as compared to patients with the *1/*15 or *15/*15 genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
							*1/*15	Patients with the *1/*15 genotype may have increased exposure to pitavastatin as compared to patients with the *1/*1 genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
							*15/*15	Patients with the *15/*15 genotype may have increased exposure to pitavastatin as compared to patients with the *1/*1 genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
	3	1450814822	rs717620	ABCC2	Metabolism/PK	pitavastatin	CC	Patients with the CC genotype may have increased exposure to pitavastatin as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
							CT	Patients with the CT genotype may have increased exposure to pitavastatin as compared to patients with the TT genotype, but decreased exposure as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
							TT	Patients with the TT genotype may have decreased exposure to pitavastatin as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		
降脂药|普伐他汀|Pravastatin	2A	981345293	rs4149056	SLCO1B1	Metabolism/PK	pravastatin	CC	Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		
							CT	Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		
							TT	Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		
	2B	655384621	rs20455	KIF6	Efficacy	pravastatin	AA	Patients with the rs20455 AA genotype may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to pravastatin treatment.		
							AG	Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.		
							GG	Patients with the rs20455 GG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.		
免疫抑制剂|泼尼松龙|prednisolone	3	1444704881	rs1045642	ABCB1	Toxicity	methylprednisolone;prednisolone	AA	Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		
							AG	Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		
							GG	Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		
	3	1445402144	rs2229109	ABCB1	Efficacy	doxorubicin;methotrexate;prednisolone;vincristine	CC	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.		
							CT	Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		
							TT	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		
	3	1448632697	rs738409	PNPLA3	Toxicity	asparaginase;cyclophosphamide;daunorubicin;prednisolone;vincristine	CC	Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
							CG	Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
							GG	Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.		
	3	1449576983	rs3828743	DSE;TSPYL1	Efficacy	abiraterone;prednisolone	AA	Patients with the AA genotype may have worse response and shorter progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.		
							AG	Patients with the AG genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.		
							GG	Patients with the GG genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.		
免疫抑制剂|泼尼松（强的松）|prednisone	3	1043880851	rs4553808	CTLA4	Toxicity	bortezomib;dexamethasone;melphalan;prednisone	AA	Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
							AG	Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
							GG	Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.		
	3	1184512128	rs3824662	GATA3	Efficacy	asparaginase;cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;leucovorin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							AC	Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
							CC	Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		
	3	1447945850	rs2229109	ABCB1	Toxicity	bleomycin;cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine;vindesine	CC	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
							CT	Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
							TT	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		
	3	1447990283	rs639174	DROSHA	Toxicity	cyclophosphamide;cytarabine;daunorubicin;mercaptopurine;methotrexate;prednisone;vincristine	CC	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
							CT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
							TT	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.		
	3	1448098793	rs17021408		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099059	rs1891059		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099093	rs117532069	DOK5	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099112	rs79085477	BMP7	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	CC	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							CT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							TT	Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099135	rs141059755	LINC00251	Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							AG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
							GG	Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.		
	3	1448099430	rs80223967		Toxicity	cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;methotrexate;pegaspargase;prednisone;thioguanine;vincristine	AA	Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							AG	Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
							GG	Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.		
	3	1448099828	rs1801157	CXCL12	Efficacy	alemtuzumab;chlorambucil;cyclophosphamide;fludarabine;prednisone;rituximab;vincristine	CC	Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.		
							CT	Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.		
							TT	Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.		
	3	1448102294	rs3957357	GSTA1	Efficacy	cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine	AA	Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.		
							AG	Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.		
							GG	Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.		
	3	655388022	rs1045642	ABCB1	Other	prednisone;tacrolimus	AA	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		
							AG	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		
							GG	Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		
高血压药|普萘洛尔|Propranolol	3	1447959515	rs1042713	ADRB2	Efficacy	propranolol	AA	Patients with the AA genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.		
							AG	Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA genotype, but decreased response compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propranolol.		
							GG	Patients with the GG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.		
	3	1451359886	rs4680	COMT	Efficacy	propranolol	AA	Patients with temporomandibular disorder (TMD) and the rs4680 AA genotype may have an increased response to propranolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.		
							AG	Patients with temporomandibular disorder (TMD) and the rs4680 AG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.		
							GG	Patients with temporomandibular disorder (TMD) and the rs4680 GG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.		
骨质疏松|雷洛昔芬|Raloxifene	3	1043858872	rs8060157	ZNF423	Efficacy	raloxifene;tamoxifen	AA	Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.		
							AG	Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.		
							GG	Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.		
	3	1043858877	rs10030044		Efficacy	raloxifene;tamoxifen	GG	Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.		
							GT	Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.		
							TT	Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.		
	3	1448259308	rs11543791	ESR1	Efficacy	raloxifene	CC	Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene.		
							CT	Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.		
							TT	Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.		
	3	1448259317	rs1042597	UGT1A8	Efficacy	raloxifene	CC	Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene.		
							CG	Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene.		
							GG	No patients with the GG genotype were studied.		
	3	1451162986	UGT1A1*1, UGT1A1*28	UGT1A1	Efficacy	raloxifene	*1/*1	Women with the UGT1A1*1/*1 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.		
							*1/*28	Women with the UGT1A1*1/*28 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.		
							*28/*28	Women with the UGT1A1*28/*28 genotype and osteoporosis may have increased hip bone mineral density when treated with raloxifene as compared to patients with the *1/*1 or *1/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.		
	3	1451163060	UGT1A1*1, UGT1A1*28	UGT1A1	Metabolism/PK	raloxifene	*1/*1	Women with the UGT1A1*1/*1 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.		
							*1/*28	Women with the UGT1A1*1/*28 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.		
							*28/*28	Women with the UGT1A1*28/*28 genotype and osteoporosis may have increased metabolism of raloxifene as compared to patients with the *1/*1 or *1/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.		
生物制剂|利妥昔单抗|Rituximab	2B	1444608384	rs396991	FCGR3A	Efficacy	rituximab	AA	Patients with the rs396991 AA genotype may have a decreased response to rituximab, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to rituximab.		
							AC	Patients with the rs396991 AC genotype may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.		
							CC	Patients with the rs396991 CC genotype may have an increased response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab.		
抗凝药|利伐沙班|Rivaroxaban	3	1448532196	rs1045642	ABCB1	Metabolism/PK	rivaroxaban	AA	People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		
							AG	People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		
							GG	People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		
	3	1448532211	rs2032582	ABCB1	Metabolism/PK	rivaroxaban	AA	People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		
							AC	People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		
							CC	People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		
							CT	People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		
							TT	People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		
	3	1451510621	rs1045642	ABCB1	Toxicity	rivaroxaban	AA	Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		
							AG	Patients with the rs1045642 AG genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		
							GG	Patients with the rs1045642 GG genotype may have increased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		
降脂药|瑞舒伐他汀|Rosuvastatin	2A	1154221922	rs2231142	ABCG2	Efficacy	rosuvastatin	GG	Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.		
							GT	Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		
							TT	Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.		
	2A	1451243453	rs2231142	ABCG2	Metabolism/PK	rosuvastatin	GG	Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have lower concentration of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to rosuvastatin treatment and rosuvastatin pharmacokinetics.This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		
							GT	Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have higher concentration of rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin treatment and rosuvastatin pharmacokinetics.This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		
							TT	Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have higher concentration of rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin treatment and rosuvastatin pharmacokinetics.This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.		
	2A	981345350	rs4149056	SLCO1B1	Metabolism/PK	rosuvastatin	CC	Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		
							CT	Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		
							TT	Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		
降脂药|辛伐他汀片|Simvastatin	1A	1451526333	SLCO1B1*1, SLCO1B1*5	SLCO1B1	Toxicity	simvastatin	*1	Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.	Normal function	
							*5	Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.	No function	
	1A	655384011	rs4149056	SLCO1B1	Toxicity	simvastatin	CC	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CC genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		
							CT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		
							TT	The C allele of SLCO1B1 rs4149056 is assigned a decreased function allele by CPIC. Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		
免疫抑制剂|雷帕霉素（西罗莫司）|Sirolimus	3	1043880082	rs1042597	UGT1A8	Toxicity	cyclosporine;mycophenolate mofetil;sirolimus;tacrolimus	CC	Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							CG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
							GG	Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.		
	3	1183614761	rs1128503	ABCB1	Toxicity	sirolimus	AA	Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels.		
							AG	Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.		
							GG	Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.		
	3	1183614840	rs1045642	ABCB1	Toxicity	sirolimus	AA	Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		
							AG	Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		
							GG	Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		
	3	1183689987	rs2740574	CYP3A4	Other	sirolimus	CC	Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.		
							CT	Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.		
							TT	Transplant recipients with the TT (CYP3A4 *1/*1) genotype may require a decreased dose of sirolimus as compared to patients with the CC (*1B/*1B) or CT (*1B/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.		
	3	1444694373	rs7903146	TCF7L2	Toxicity	cyclosporine;sirolimus;tacrolimus	CC	Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
							CT	Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
							TT	Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.		
	3	1448567797	rs1057868	POR	Metabolism/PK	sirolimus	CC	Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.		
							CT	Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.		
							TT	Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.		
	3	1448567993	rs1800896	IL10	Metabolism/PK	sirolimus	CC	Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.		
							CT	Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.		
							TT	Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.		
	3	1449140063	rs3814055	NR1I2	Toxicity;Metabolism/PK	sirolimus;temsirolimus	CC	Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype, and an increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.		
							CT	Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.		
							TT	Patients with the TT genotype and bladder cancer may have decreased metabolism of temsirolimus as compared to patients with the CC or CT genotypes, and an decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.		
	3	1449140069	rs6785049	NR1I2	Toxicity;Metabolism/PK	sirolimus;temsirolimus	AA	Patients with the AA genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and increased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.		
							AG	Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.		
							GG	Patients with the GG genotype and bladder cancer who are treated with temsirolimus may have increased exposure as compared to patients with the AA or AG genotypes and decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.		
	3	1449140085	rs2032582	ABCB1	Metabolism/PK	sirolimus;temsirolimus	AA	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		
							AC	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		
							CC	Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus or sirolimus as compared to patients with the AA or AC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		
	3	1449140229	rs1128503	ABCB1	Metabolism/PK	sirolimus;temsirolimus	AA	Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		
							AG	Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		
							GG	Patients with the GG genotype and bladder cancer may have decreased exposure to sirolimus and temsirolimus as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		
	3	1451286280	CYP3A5*1, CYP3A5*3	CYP3A5	Dosage	sirolimus	*1	Patients with the *1 allele in combination with another normal function allele may require higher dose of sirolimus as compared to patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may require higher dose of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.	Normal function	
							*3	Patients with the *3 allele in combination with another no function allele may require lower doses of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or a patients with two normal function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.	No function	
	3	981203936	CYP3A5*1, CYP3A5*3	CYP3A5	Metabolism/PK	sirolimus	*1	Patients with the *1 allele in combination with another normal function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles or patients with *1 allele in combination with a no function allele, while patients with the *1 allele in combination with another no function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.	Normal function	
							*3	Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.	No function	
高血压药|螺内酯|Spironolactone	3	1444700983	rs1799983	NOS3	Efficacy	Ace Inhibitors, Plain;Angiotensin II Antagonists;Beta Blocking Agents;digoxin;diuretics;spironolactone	GG	Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.		
							GT	Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients.		
							TT	Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.		
	3	1447960179	rs1042713	ADRB2	Efficacy	Ace Inhibitors, Plain;Angiotensin II Antagonists;Beta Blocking Agents;digoxin;diuretics;spironolactone	AA	Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
							AG	Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
							GG	Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
	3	1447960443	rs1801253	ADRB1	Efficacy	Ace Inhibitors, Plain;Angiotensin II Antagonists;Beta Blocking Agents;digoxin;diuretics;spironolactone	CC	Patients with the rs1801253 CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
							CG	Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
							GG	Patients with the rs1801253 GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.		
	3	1450821121	rs1126742	CYP4A11	Efficacy	amiloride;spironolactone	AA	Patients with hypertension and the AA genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.		
							AG	Patients with hypertension and the AG genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.		
							GG	Patients with hypertension and the GG genotype may have a decreased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.		
	3	1450821128	rs3890011	CYP4A11	Efficacy	spironolactone	CC	Patients with hypertension and the CC genotype may have a decreased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to spironolactone.		
							CG	Patients with hypertension and the CG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.		
							GG	Patients with hypertension and the GG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.		
	3	769143802	rs4343	ACE	Efficacy	spironolactone	AA	Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.		
							AG	Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.		
							GG	Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.		
	3	981202806	rs4961	ADD1	Efficacy	furosemide;spironolactone	GG	Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
							GT	Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
							TT	Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.		
免疫抑制剂|柳氮磺吡啶|Sulfasalazine	3	1184642788	G6PD A- 202A_376G, G6PD B (wildtype)	G6PD	Toxicity	sulfasalazine	A- 202A_376G	Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.	Class III	
							A- 202A_376G/A- 202A_376G	Female patients with the A- 202A_376G/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B/B diplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
							A- 202A_376G/B (wildtype)	Female patients with the A- 202A_376G/B (wildtype) diplotype (heterozygous for the G6PD A- variant) who are treated with sulfasalazine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G/A- 202A_376G or B/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
							B (wildtype)	Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.	Class IV	
							B (wildtype)/B (wildtype)	Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.		
	3	1444686824	rs2231142	ABCG2	Efficacy	sulfasalazine	GG	Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		
							GT	Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		
							TT	Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.		
	3	1446899372	rs2231142	ABCG2	Metabolism/PK	sulfasalazine	GG	Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.		
							GT	Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.		
							TT	Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.		
	3	1448099454	rs72552713	ABCG2	Metabolism/PK	sulfasalazine	AG	Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).		
							GG	Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).		
免疫抑制剂|他克莫司|Tacrolimus	1A	1451214480	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	CYP3A5	Metabolism/PK	tacrolimus	*1	The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *1 allele in combination with a normal or no function allele may have increased metabolism of tacrolimus as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	Normal function	
							*3	The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	No function	
							*6	The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *6 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	No function	
							*7	The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *7 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	No function	
	1A	981203719	CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7	CYP3A5	Dosage	tacrolimus	*1	The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*1 allele in combination with a normal or no function allele may have increased tacrolimus dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.	Normal function	
							*3	The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.	No function	
							*6	The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*6 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.	No function	
							*7	The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*7 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.	No function	
	1B	1183689931	CYP3A4*1, CYP3A4*1G, CYP3A4*18, CYP3A4*20, CYP3A4*22	CYP3A4	Metabolism/PK	tacrolimus	*1	Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.		
							*18	Patients carrying two copies of the CYP3A4*18 allele or one copy of the *18 allele in combination with one copy of the *1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.		
							*1G	Patients with two copies of the CYP3A4*1G allele or one copy of the *1G allele in combination with one copy of the *1 allele may have increased metabolism of tacrolimus as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.		
							*20	Patients carrying one copy of the CYP3A4*20 allele in combination with one copy of the *1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.		
							*22	Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may have decreased metabolism of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.		
	1B	1184999911	CYP3A5*1, CYP3A5*3	CYP3A5	Metabolism/PK	tacrolimus	*1	Patients undergoing a liver transplant who have the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	Normal function	
							*3	Patients undergoing a liver transplant who have the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients who have the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	No function	
	1B	1451241780	CYP3A5*1, CYP3A5*3	CYP3A5	Metabolism/PK	tacrolimus	*1	Patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a normal function allele in combination with a no function allele or a donor with two no function alleles, while patients who receive a liver transplant from a donor with the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	Normal function	
							*3	Patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a no function allele in combination with a normal function allele or a donor with two normal function alleles, while patients who receive a liver transplant from a donor with the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.	No function	
	2A	1444686843	rs4646437	CYP3A4	Metabolism/PK	tacrolimus	AA	Patients with the rs4646437 AA genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.		
							AG	Patients with the rs4646437 AG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype, or decreased concentrations as compared to the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.		
							GG	Patients with the rs4646437 GG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.		
	2A	1451241700	CYP3A5*1, CYP3A5*3	CYP3A5	Dosage	tacrolimus	*1	Patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele or a donor with two no function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.	Normal function	
							*3	Patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele or a donor with two normal function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.	No function	
	2A	1451243216	CYP3A5*1, CYP3A5*3	CYP3A5	Dosage	tacrolimus	*1	Patients who are recipients of a liver transplant and have the CYP3A5*1 allele in combination with another normal function allele may require an increased dose of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the CYP3A5*1 allele in combination with a no function allele may require an increased dose of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.	Normal function	
							*3	Patients who are recipients of a liver transplant and have have the CYP3A5*3 allele in combination with another no function allele may require a decreased dose of tacrolimus as compared to patients with a no function allele in combination with a normal function allele or two normal function alleles, while patients who have the CYP3A5*3 allele in combination with a normal function allele may require a decreased dose of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.	No function	
	2A	1451251080	CYP3A4*1, CYP3A4*3, CYP3A4*20, CYP3A4*22	CYP3A4	Dosage	tacrolimus	*1	Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.		
							*20	Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.		
							*22	Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.		
							*3	Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*3 allele or one copy of the *3 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.		
免疫抑制剂|沙利度胺|Thalidomide	3	1043880318	rs735482	ERCC1	Efficacy	thalidomide	AA	Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
							AC	Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
							CC	Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
	3	1043880323	rs1051685	XRCC5	Efficacy	thalidomide	AA	Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
							AG	Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
							GG	Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.		
	3	1447953328	rs4135385	CTNNB1	Efficacy;Toxicity	cyclophosphamide;dexamethasone;lenalidomide;thalidomide	AA	Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							AG	Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
							GG	Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.		
	3	1447953340	rs4533622	CTNNB1	Efficacy;Toxicity	lenalidomide;thalidomide	AA	Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.		
							AC	Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.		
							CC	Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.		
	3	1448612682	rs308395	FGF2	Efficacy	lenalidomide;thalidomide	CC	Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.		
							CG	Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.		
							GG	Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.		
	3	655386093	rs7769719	PPARD	Efficacy	docetaxel;thalidomide	AA	Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386099	rs730720	CHST3	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386104	rs6922548	PPARD	Efficacy	docetaxel;thalidomide	AA	Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386109	rs4646487	CYP4B1	Toxicity	docetaxel;thalidomide	CC	Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386114	rs4148950	CHST3	Efficacy;Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386120	rs4148947	CHST3	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386126	rs4148945	CHST3	Efficacy;Toxicity	docetaxel;thalidomide	CC	Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386131	rs4148943	CHST3	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386136	rs3734254	PPARD	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386141	rs2301159	SLC10A2	Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386146	rs2292954	SPG7	Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386151	rs2238472	ABCC6	Toxicity	docetaxel;thalidomide	CC	Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386156	rs2227291	ATP7A	Toxicity	docetaxel;thalidomide	CC	Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							CG	Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386161	rs2016520	PPARD	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386166	rs1883322	PPARD	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							CT	Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		
							TT	Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386171	rs1871450	CHST3	Efficacy;Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		
	3	655386176	rs1799931	NAT2	Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386181	rs1402467	SULT1C4	Efficacy	docetaxel;thalidomide	CC	Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							CG	Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386186	rs12960	RPL13;SNORD68;SPG7	Toxicity	docetaxel;thalidomide	AA	Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.		
	3	655386191	rs12418	CHST3	Efficacy	docetaxel;thalidomide	AA	Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							AG	Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		
							GG	Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		
抗凝药|替格瑞洛|Ticagrelor	3	1448100326	rs61361928	UGT2B7	Metabolism/PK	ticagrelor	CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		
							TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.		
	3	1448100334	rs56324128	CYP3A4	Metabolism/PK	ticagrelor	CC	Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.		
							CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		
	3	1448100340	rs62471956	CYP3A43	Metabolism/PK	ticagrelor	AA	Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.		
							AG	Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.		
							GG	Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.		
	3	1448100347	rs4149056	SLCO1B1	Metabolism/PK	ticagrelor	CC	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.		
							CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		
							TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.		
	3	1448100354	rs113681054	SLCO1B1	Metabolism/PK	ticagrelor	CC	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.		
							CT	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		
							TT	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.		
	3	1448531857	rs12566888	PEAR1	Efficacy	ticagrelor	GT	Patients with the GT genotype may have higher maximal platelet aggregation as compared to patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.		
							TT	Patients with the TT genotype may have lower maximal platelet aggregation as compared to patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.		
	3	1448531862	rs12041331	PEAR1	Efficacy	ticagrelor	AA	People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.		
							AG	People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.		
							GG	People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.		
	3	1448531868	rs4661012	PEAR1	Efficacy	ticagrelor	GG	People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.		
							GT	People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.		
							TT	People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.		
高血压药|群多普利|Trandolapril	3	1446902927	rs4742610	PTPRD	Efficacy	trandolapril;verapamil	CC	Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.		
							TC	Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.		
							TT	Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.		
抗感染药|伏立康唑|voriconazole	1A	1183689217	CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17	CYP2C19	Metabolism/PK	voriconazole	*1	The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of voriconazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of voriconazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. However some studies showed no association. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.	Normal function	
							*17	The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of voriconazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.	Increased function	
							*2	The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.	No function	
							*3	The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.	No function	
抗凝药|华法林|warfarin	1A	1447672658	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11	CYP2C9	Toxicity	warfarin	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.	Normal function	
							*11	The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.	Decreased function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.	No function	
							*5	The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.	Decreased function	
							*6	The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.	No function	
	1A	1447672988	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11	CYP2C9	Toxicity	warfarin	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	Normal function	
							*11	The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	Decreased function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	No function	
							*5	The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	Decreased function	
							*6	The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.	No function	
	1A	655385012	rs9923231	VKORC1	Dosage	warfarin	CC	Patients with the rs9923231 CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.		
							CT	Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.		
							TT	Patients with the rs9923231 TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.		
	1A	655385400	rs2108622	CYP4F2	Dosage	warfarin	CC	Patients with the rs2108622 CC genotype may have decreased warfarin dosage requirements as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.		
							CT	Patients with the rs2108622 CT genotype may have increased warfarin dosage requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.		
							TT	Patients with the rs2108622 TT genotype may have increased warfarin dosage requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.		
	1A	981238341	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11	CYP2C9	Dosage	warfarin	*1	The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.	Normal function	
							*11	The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*11 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.	Decreased function	
							*2	The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.	Decreased function	
							*3	The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.	No function	
							*4	The CYP2C9*4 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*4 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.	Decreased function	
							*5	The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*5 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.	Decreased function	
							*6	The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*6 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.	No function	
							*8	The CYP2C9*8 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*8 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.	Decreased function	
	1A	982030369	rs12777823		Dosage	warfarin	AA	Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.		
							AG	Patients with the rs12777823 AG genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.		
							GG	Patients with the rs12777823 GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dosage.		
	1B	1447673005	rs9923231	VKORC1	Toxicity	warfarin	CC	Patients with the rs9923231 CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.		
							CT	Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.		
							TT	Patients with the rs9923231 TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.		
	1B	655384733	rs7294	VKORC1	Dosage	warfarin	CC	Patients with the rs7294 CC genotype may require a lower dose of warfarin as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.		
							CT	Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.		
							TT	Patients with the rs7294 TT genotype may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.		
	1B	655385024	rs2359612	VKORC1	Dosage	warfarin	AA	Patients with the rs2359612 AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.		
							AG	Patients with the rs2359612 AG genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.		
							GG	Patients with the rs2359612 GG genotype may require an increased dose of warfarin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin.		
	1B	655385028	rs8050894	VKORC1	Dosage	warfarin	CC	Patients with the rs8050894 CC genotype may require a higher dose of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.		
							CG	Patients with the rs8050894 CG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.		
							GG	Patients with the rs8050894 GG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.		
	1B	655385392	rs9934438	VKORC1	Dosage	warfarin	AA	Patients with the rs9934438 AA genotype may require a lower dose of warfarin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.		
							AG	Patients with the rs9934438 AG genotype may require a lower dose of warfarin as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence warfarin dose requirements.		
							GG	Patients with the rs9934438 GG genotype may require higher dose of warfarin as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.		
	2A	1183703748	rs61742245	VKORC1	Dosage	warfarin	AA	Patients with the rs61742245 AA genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.		
							AC	Patients with the rs61742245 AC genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.		
							CC	Patients with the rs61742245 CC genotype may have require a decreased dose of warfarin as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.		
	2A	1447672600	CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*13, CYP2C9*14	CYP2C9	Efficacy	warfarin	*1	Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.	Normal function	
							*13	Patients with CYP2C9*13 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.	No function	
							*14	Patients with CYP2C9*14 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.	Decreased function	
							*2	Patients with CYP2C9*2 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.	Decreased function	
							*3	Patients with CYP2C9*3 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.	No function	
	2A	1447672998	rs9923231	VKORC1	Efficacy	warfarin	CC	Patients with the rs9923231 CC genotype may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
							CT	Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
							TT	Patients with the rs9923231 TT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
	2A	1447673015	rs9923231	VKORC1	Efficacy	warfarin	CC	Patients with the rs9923231 CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
							CT	Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
							TT	Patients with the rs9923231 TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.		
	2A	1449269910	rs9923231	VKORC1	Toxicity	warfarin	CC	Patients with the rs9923231 CC genotype may have a decreased risk of bleeding when treated with warfarin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.		
							CT	Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.		
							TT	Patients with the rs9923231 TT genotype may have an increased risk of bleeding when treated with warfarin as compared to the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.		
	2A	982035703	rs2884737	VKORC1	Dosage	warfarin	AA	Patients with the rs2884737 AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.		
							AC	Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.		
							CC	Patients with the rs2884737 CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.		
